

10/06/99
1c714 U.S. PTO

A

EXPRESS MAIL MAILING LABEL	
NUMBER EL 259186668 US	
DATE OF DEPOSIT	October 6, 1999

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Dkt. No.: INRP:087/SHS

**Prior Application Examiner:
Guzo, D**

**Classification Designation:
unknown**

Prior Group Art Unit: 1805

BOX PATENT APPLICATION
Assistant Commissioner for Patents
Washington, D.C. 20231

1c678 U.S. PTO
09/413109
56/90/01
10/06/99

**REQUEST FOR FILING DIVISIONAL APPLICATION
UNDER 37 C.F.R. § 1.53(b)**

This is a request for filing a divisional application under Rule 53(b) (37 C.F.R. § 1.53(b)) of co-pending prior application Serial No. 08/145,826 filed October 29, 1993, entitled "RECOMBINANT P53 ADENOVIRUS METHODS AND COMPOSITIONS."

- ☒ 1. Enclosed is a copy of the prior application Serial No. 08/145,826 as originally filed, including specification, claims, drawings, and declaration. The undersigned hereby verifies that the attached papers are a true copy of the prior application as originally filed and identified above, that no amendments (if any) referred to in the declaration filed to complete the prior application introduced new matter therein, and further that this statement was made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment or both, under Section 1001 of Title 18 of the United States Code, and that such

willful false statement may jeopardize the validity of the application or any patent issuing thereon.

(a) ☒ The inventorship is the same as prior Application Serial No. 08/145,826 filed October 29, 1993, which is a Continuation-in-part of 07/960,513 filed October 13, 1992.

(b) ☐ Deletion of inventor(s). Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. § 1.63(d)(2) and 1.33(b).

(c) ☐ Priority of foreign patent application number _____, filed _____ in _____ is claimed under 35 U.S.C. § 119(a)-(e). The certified copy:
☐ is enclosed.
☐ has been filed in the prior Application Serial No. _____

☒ 2. Enclosed is a check in the amount of \$1,426 to cover the filing fee as calculated below and the fee for any new claims added in the Preliminary Amendment referred to in Clause No. 7 below.

CLAIMS AS FILED IN THE PRIOR APPLICATION
LESS CLAIMS CANCELED BELOW


FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
Basic Fee -----				\$760.00
Total Claims	57 - 20 =	37 X	\$18.00 =	\$666.00
Independent Claims	3 - 3 =	0 X	\$78.00 =	\$.00
Multiple Dependent Claim(s) -----				\$-0-.00
TOTAL FILING FEES:				\$1,426.00

- ☐ 3. Applicant is entitled to Small Entity Status for this application.
- ☐ (a) A small entity statement is enclosed.
- ☐ (b) A small entity statement was filed in the prior nonprovisional application and such status is still proper and desired.
- ☐ (c) Small entity status is no longer claimed.
- ☒ 4. If the check is missing or insufficient, the Assistant Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16 to 1.21 which may be required for any reason relating to this application, or credit any overpayment to Arnold White & Durkee Deposit Account No. 01-2508/INRP:087/SHS.
- ☐ 5. Enclosed is a copy of the current Power of Attorney in the prior application.
- ☒ 6. Address all future communications to:
- Gina N. Shishima
ARNOLD WHITE & DURKEE
P.O. Box 4433
Houston, Texas 77210
(713) 787-1400
- ☒ 7. The prior application is presently assigned to Introgen Therapeutics, Inc.
- ☒ 8. Enclosed is a preliminary amendment. Any additional fees incurred by this amendment are included in the check at No. 2 above and said fee has been calculated after calculation of claims and after amendment of claims by the preliminary amendment.
- ☐ 9. Cancel in this application claims 1-42 of the prior application before calculating the filing fee. (At least one original independent claim must be retained).

- ☐ 10. Amend the specification by inserting before the first line the sentence: --This is a divisional of co-pending application Serial No. 08/145,826 filed October 29, 1993 which is a continuation-in-part of 07/960,513 filed October 13, 1992--.
- ☐ 11. Enclosed are formal drawings.
- ☐ 12. An Information Disclosure Statement (IDS) is enclosed.
- ☐ (a) PTO-1449.
- ☐ (b) Copies of IDS citations.
- ☒ 13. Transfer the sequence information, including the computer readable form previously submitted in the parent application, Serial No. 08/145,826 filed October 29, 1993, for use in this application. Under 37 C.F.R. § 1.821(e), Applicant states that the paper copy of the sequence listing in this application is identical to the computer readable copy in parent application Serial No. 08/145,826 filed October 29, 1993. Under 37 C.F.R. § 1.821(f), Applicant also states that the information recorded in computer readable form is identical to the written sequence listing.
- ☒ 14. Other:. Request for Transfer of Sequence Listing.
- ☒ 15. Return Receipt Postcard (should be specifically itemized).

Should the Examiner have any questions regarding this submission, he is invited to contact the undersigned at her desk telephone at (512) 418-3081.

Respectfully submitted,



Gina N. Shishima

Reg. No. P-45,104

Attorney for Applicants

ARNOLD, WHITE & DURKEE
P.O. Box 4433
Houston, Texas 77210
(512) 418-3000

Date: October 6, 1999

2025 RELEASE UNDER E.O. 14176

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<i>In re</i> Application of	§	
Wei-Wei Zhang	§	
and Jack Roth	§	
	§	Prior Group Art Unit: 1805
DIV of Serial No. 08/145,826	§	
	§	
Filed: Concurrently Herewith	§	Prior Examiner: Guzo, D.
	§	
For: SYSTEMIC ADMINISTRATION OF	§	Atty. Dkt.: INRP:087/SHS
ADENOVIRUS p53	§	
	§	
	§	
	§	
	§	

EXPRESS MAIL MAILING LABEL
NUMBER EL 259186668 US
DATE OF DEPOSIT October 6, 1999

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to examination of the above-captioned application, applicants respectfully request that the following amendments to the claims be entered. No fees are believed due in connection with this filing beyond those fees enclosed. Should the Commissioner determine otherwise, he is authorized to debit the deficiency to ARNOLD, WHITE & DURKEE Deposit Acct. No. 01-2508/INRP:087/SHS.

I. AMENDMENTS

IN THE SPECIFICATION:

At page 1, please delete the existing title and insert therefor the following:--SYSTEMIC
ADMINISTRATION OF ADENOVIRUS p53--.

At page 2, line 3, please delete the first paragraph and insert therefor the following: --This is a
divisional of co-pending application Serial No. 08/145,826 filed October 29, 1993 which is a
continuation-in-part of 07/960,513 filed October 13, 1992, the entire text of which is herein
incorporated by reference without disclaimer. The government owns rights in the present
invention pursuant to NIH grants RO1 CA 45187 and CA 16672--.

IN THE CLAIMS:

Please cancel claims 1-42 without prejudice or disclaimer.

Please add the following new claims:

- 43. A method of treating a human cancer patient having a human malignancy, comprising
administering regionally to said patient an amount of an adenovirus composition effective
to prevent growth of malignant cells, wherein said adenovirus composition comprises an
adenovirus vector construct comprising a p53 gene, dispersed in a pharmacologically
acceptable solution.
44. The method of claim 43, wherein said adenoviral composition is administered to the
patient by infusion over a period of time.

45. The method of claim 44, wherein said period of time is about 48 hours.
46. The method of claim 43, wherein said amount comprises between about 10^3 to about 5×10^{12} adenovirus particles.
47. The method of claim 46, wherein said amount comprises between about 10^3 to about 10^6 adenovirus particles.
48. The method of claim 46, wherein said amount comprises between about 1×10^{10} to about 5×10^{12} adenovirus particles.
49. The method of claim 46, wherein said amount comprises about 1×10^{10} virus particles.
50. The method of claim 46, wherein said amount comprises about 3×10^{10} virus particles.
51. The method of claim 46, wherein said amount comprises about 5×10^{12} adenovirus particles.
52. The method of claim 43, further comprising at least a second administration of the adenoviral composition.
53. The method of claim 52, further comprising at least a third administration of the adenoviral composition.
54. The method of claim 53, wherein the third administration occurs at least about one day after the second administration.
55. The method of claim 53, wherein the third administration occurs about one day after the second administration.

56. The method of claim 53, wherein said first, second, and third administrations are each given on three consecutive days.
57. The method of claim 43, further comprising resecting a tumor of said cancer patient.
58. The method of claim 43, wherein said resecting occurs prior to said administering.
59. The method of claim 43, wherein said adenoviral composition further comprises phosphate-buffered saline with about 1% (v/v) glycerol.
60. The method of claim 43, wherein said adenoviral composition is delivered in a volume of about 10 ml or less.
61. The method of claim 43, wherein the wild-type p53 gene is under the control of a CMV promoter.
62. The method of claim 43, wherein said growth is prevented by apoptosis.
63. A method of treating a human cancer patient comprising administering intravenously to said patient an amount of an adenovirus composition effective to prevent growth of malignant cells, wherein said adenovirus composition comprises an adenovirus vector construct comprising a p53 gene, dispersed in a pharmacologically acceptable solution.
64. The method of claim 63, wherein said adenoviral composition is administered to the patient by intravenous infusion over a period of time.
65. The method of claim 64, wherein said period of time is about 48 hours.
66. The method of claim 63, wherein said amount comprises between about 10^3 to about 5×10^{12} adenovirus particles.

67. The method of claim 66, wherein said amount comprises between about 10^3 to about 10^6 adenovirus particles.
68. The method of claim 66, wherein said amount comprises between about 1×10^{10} to about 5×10^{12} adenovirus particles.
69. The method of claim 63, further comprising at least a second administration of the adenoviral composition.
70. The method of claim 69, further comprising at least a third administration of the adenoviral composition.
71. The method of claim 70, wherein the third administration occurs at least about one day after the second administration.
72. The method of claim 70, wherein the third administration occurs about one day after the second administration.
73. The method of claim 70, wherein said first, second, and third administrations are each given on three consecutive days.
74. The method of claim 63, further comprising resecting a tumor of said cancer patient.
75. The method of claim 63, wherein said resecting occurs prior to said administering.
76. The method of claim 63, wherein said adenoviral composition further comprises phosphate-buffered saline with about 1% (v/v) glycerol.

77. The method of claim 63, wherein said adenoviral composition is delivered in a volume of about 10 ml or less.
78. The method of claim 63, wherein the wild-type p53 gene is under the control of a CMV promoter.
79. The method of claim 63, wherein said growth is prevented by apoptosis.
80. A method of treating a human cancer patient comprising instilling intratracheally to said patient an amount of an adenovirus composition effective to prevent growth of malignant cells, wherein said adenovirus composition comprises an adenovirus vector construct comprising a p53 gene, dispersed in a pharmacologically acceptable solution.
81. The method of claim 80, wherein said adenoviral composition is administered to the patient by infusion over a period of time.
82. The method of claim 81, wherein said period of time is about 48 hours.
83. The method of claim 80, wherein said amount comprises between about 10^3 to about 5×10^{12} adenovirus particles.
84. The method of claim 80, wherein said amount comprises between about 10^3 to about 10^6 adenovirus particles.
85. The method of claim 84, wherein said amount comprises between about 1×10^{10} to about 5×10^{12} adenovirus particles.
86. The method of claim 84, wherein said amount comprises about 1×10^{10} virus particles.
87. The method of claim 84, wherein said amount comprises about 3×10^{10} virus particles.

88. The method of claim 84, wherein said amount comprises about 5×10^{12} adenovirus particles.
89. The method of claim 80, further comprising at least a second administration of the adenoviral composition.
90. The method of claim 89, further comprising at least a third administration of the adenoviral composition.
91. The method of claim 90, wherein the third administration occurs at least about one day after the second administration.
92. The method of claim 90, wherein the third administration occurs about one day after the second administration.
93. The method of claim 90, wherein said first, second, and third administrations are each given on three consecutive days.
94. The method of claim 80, further comprising resecting a tumor of said cancer patient.
95. The method of claim 80, wherein said resecting occurs prior to said administering.
96. The method of claim 80, wherein said adenoviral composition further comprises phosphate-buffered saline with about 1% (v/v) glycerol.
97. The method of claim 80, wherein said adenoviral composition is delivered in a volume of about 10 ml or less.

98. The method of claim 80, wherein the wild-type p53 gene is under the control of a CMV promoter.
99. The method of claim 80, wherein said growth is prevented by apoptosis. --

REMARKS


The independent claims as submitted in this Divisional Application have been previously deemed allowable in dependent form as contained in Application Serial. No. 08/626,678, now subject to an interference proceeding. These allowable claims were amended to place them in independent form herein. Applicants submit that the subject matter of the independent claims as submitted in this Divisional Application is not the subject matter that is presently the basis of the interference.

Support for the amended claims may be found throughout the specification, including at: page 42, line 20; page 42, line 27; page 39, lines 26-7; page 42, line 9; page 42, line 28; page 8, line 28; page 9, line 1; page 43, line 13; page 7, lines 5-6; page 5, line 26; page 6, line 3 page 42, line 25; and page 43, line 3. Thus, no new matter has been added.

Claims 1-42 have been canceled without prejudice or disclaimer. New claims 43-99 have been added. Thus, claims 43-99 are pending.

Should the Examiner have any questions regarding this submission, he is invited to contact the undersigned at her desk telephone at (512) 418-3081.

Respectfully submitted,



Gina N. Shishima

Reg. No. P-45,104

Attorney for Applicants

ARNOLD, WHITE & DURKEE

P.O. Box 4433

Houston, Texas 77210

(512) 418-3000

Date: October 6, 1999

RECOMBINANT P53 ADENOVIRUS
METHODS AND COMPOSITIONS

By

WEI-WEI ZHANG

and

JACK A. ROTH

"Express Mail" Mailing Label

Number EL 259186668 US

Date of Deposit October 6, 1999

"EXPRESS MAIL" MAILING LABEL

NUMBER RB710384411US

DATE OF DEPOSIT OCTOBER 29, 1993

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING
DEPOSITED WITH THE UNITED STATES POSTAL SERVICE
"EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE
UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS
ADDRESSED TO THE COMMISSIONER OF PATENTS AND
TRADEMARKS, WASHINGTON, D.C. 20231.

LEO MOLINA

(TYPED OR PRINTED NAME OF PERSON MAILING PAPER OR
FEE)

(SIGNATURE OF PERSON MAILING PAPER OR FEE)

BACKGROUND OF THE INVENTION

The present application is a continuation-in-part of co-pending U.S. Patent Application Serial Number 07/960,543, filed October 13, 1992, the entire text of which is
5 herein incorporated by reference without disclaimer. The government owns rights in the present invention pursuant to NIH grants RO1 CA 45187 and CA 16672.

1. Field of the Invention

10 The present invention relates generally to the area of recombinant technology. In some aspects, it concerns simplified and efficient methods of generating recombinant adenovirus. In other aspects, novel compositions and methods involving p53 adenovirus constructs are provided, including methods for restoring normal p53 functions and growth
15 suppression to cells with abnormal p53.

2. Description of Related Art

Current treatment methods for cancer, including radiation therapy, surgery, and chemotherapy, are known to have limited effectiveness. Lung cancer alone kills more than
20 140,000 people annually in the United States. Recently, age-adjusted mortality from lung cancer has surpassed that from breast cancer in women. Although implementation of smoking-reduction programs has decreased the prevalence of smoking, lung cancer mortality rates will remain high well into the 21st century. The rational development of new therapies for lung cancer will depend on an understanding of the biology of lung cancer at the
25 molecular level.

It is now well established that a variety of cancers are caused, at least in part, by genetic abnormalities that result in either the over expression of one or more genes, or the expression of an abnormal or mutant gene or genes. For example, in many cases, the

expression of oncogenes is known to result in the development of cancer. "Oncogenes" are genetically altered genes whose mutated expression product somehow disrupts normal cellular function or control (Spandidos *et al.*, 1989).

5 Most oncogenes studied to date have been found to be "activated" as the result of a mutation, often a point mutation, in the coding region of a normal cellular gene, *i.e.*, a "proto-oncogene", that results in amino acid substitutions in the expressed protein product. This altered expression product exhibits an abnormal biological function that takes part in the neoplastic process (Travali *et al.*, 1990). The underlying mutations can arise by various
10 means, such as by chemical mutagenesis or ionizing radiation. A number of oncogenes and oncogene families, including *ras*, *myc*, *neu*, *raf*, *erb*, *src*, *fms*, *jun* and *abl*, have now been identified and characterized to varying degrees (Travali *et al.*, 1990; Bishop, 1987).

During normal cell growth, it is thought that growth-promoting proto-oncogenes are counterbalanced by growth-constraining tumor suppressor genes. Several factors may contribute to an imbalance in these two forces, leading to the neoplastic state. One such factor is mutations in tumor suppressor genes (Weinberg, 1991).

An important tumor suppressor gene is the gene encoding the cellular protein, p53, which is a 53 kD nuclear phosphoprotein that controls cell proliferation. Mutations to the p53 gene and allele loss on chromosome 17p, where this gene is located, are among the most frequent alterations identified in human malignancies. The p53 protein is highly conserved through evolution and is expressed in most normal tissues. Wild-type p53 has been shown to be involved in control of the cell cycle (Mercer, 1992), transcriptional regulation (Fields
25 *et al.*, 1990, and Mietz *et al.*, 1992), DNA replication (Wilcock and Lane, 1991, and Bargonetti *et al.*, 1991), and induction of apoptosis (Yonish-Rouach *et al.*, 1991, and, Shaw *et al.*, 1992).

Various mutant p53 alleles are known in which a single base substitution results in the synthesis of proteins that have quite different growth regulatory properties and, ultimately, lead to malignancies (Hollstein *et al.*, 1991). In fact, the p53 gene has been found to be the most frequently mutated gene in common human cancers (Hollstein *et al.*, 1991; Weinberg, 1991), and is particularly associated with those cancers linked to cigarette smoke (Hollstein *et al.*, 1991; Zakut-Houri *et al.*, 1985). The overexpression of p53 in breast tumors has also been documented (Casey *et al.*, 1991).

One of the most challenging aspects of gene therapy for cancer relates to utilization of tumor suppressor genes, such as p53. It has been reported that transfection of wild-type p53 into certain types of breast and lung cancer cells can restore growth suppression control in cell lines (Casey *et al.*, 1991; Takahasi *et al.*, 1992). Although DNA transfection is not a viable means for introducing DNA into patients' cells, these results serve to demonstrate that supplying wild type p53 to cancer cells having a mutated p53 gene may be an effective treatment method if an improved means for delivering the p53 gene could be developed.

Gene delivery systems applicable to gene therapy for tumor suppression are currently being investigated and developed. Virus-based gene transfer vehicles are of particular interest because of the efficiency of viruses in infecting actual living cells, a process in which the viral genetic material itself is transferred. Some progress has been made in this regard as, for example, in the generation of retroviral vectors engineered to deliver a variety of genes. However, major problems are associated with using retroviral vectors for gene therapy since their infectivity depends on the availability of retroviral receptors on the target cells, they are difficult to concentrate and purify, and they only integrate efficiently into replicating cells.

Adenovirus vector systems have recently been proposed for use in certain gene transfer protocols, however, the current methods for preparing recombinant adenovirus have several drawbacks. These methods rely on calcium phosphate-mediated transfection of

markedly reduce the growth rate of transformed cells. The virus inhibited tumorigenicity of virus-infected H358 cells. Furthermore it prevented orthotopic lung cancer growth when the virus was instilled intratracheally following the intratracheal inoculation of the H226Br cells. The inhibition of tumorigenicity also suggests that even transient expression of a high-level of the p53 protein may be enough to induce a tumoricidal effect.

In one specific embodiment, this invention concerns vector constructs for introducing wild type p53 genes into target cells, such as target cells suspected of having mutant or aberrant p53 genes, including malignant cell types. These embodiments involve the preparation of a gene expression or transcription unit wherein the p53 gene is placed under the control of a promoter and the unit is incorporated into an adenoviral vector within a recombinant adenovirus. The invention as a whole is surprising and advantageous for several reasons. Firstly, it was previously thought that p53 virus could not be generated into a packaging cell, such as those used to prepare adenovirus, as it would be toxic; secondly, E1B of adenovirus binds to p53 and thus interferes with its function; thirdly, once generated, the p53 adenovirus was found to be unexpectedly effective at inhibiting the growth of various cancer cells; and finally the tumorigenicity of the lung cancer cells was inhibited through the treatment by Ad5CMV-p53 but not a control virus indicating that the novel p53 protein delivery and preparation has astonishing therapeutic efficacy.

The invention therefore concerns adenovirus vector constructs that involve using Adenovirus to carry tumor suppressor genes such as p53, anti-sense oncogenes and other related genes for human cancer therapy. In one embodiment recombinant Adenovirus virions or particles incorporating such vectors, and pharmacological formulations thereof, which comprise a recombinant insert including an expression region encoding wild type p53, by which vectors are capable of expressing p53 in human metastatic cells are encompassed. The p53 expression region in the vector may comprise a genomic sequence, but for simplicity, it is contemplated that one will generally prefer to employ a p53 cDNA sequence as these are readily available in the art and more easily manipulated. The recombinant insert of the

vector will also generally comprise a promoter region and a polyadenylation signal, such as an SV40 or protamine gene polyadenylation signal.

In preferred embodiments, it is contemplated that one will desire to position the p53 expression region under the control of a strong constitutive promoter such as a CMV promoter, viral LTR, RSV, or SV40 promoter, or a promoter associated with genes that are expressed at high levels in mammalian cells such as elongation factor-1 or actin promoters. Currently, the most preferred promoter is the cytomegalovirus (CMV) IE promoter.

The p53 gene or cDNA may be introduced into recombinant adenovirus in accordance with the invention simply by inserting or adding the p53 coding sequence into a viral genome which lacks E1B. However, the preferred adenoviruses will be replication defective viruses in which a viral gene essential for replication and/or packaging has been deleted from the adenoviral vector construct, allowing the p53 expression region to be introduced in its place. Any gene in addition to E1B, whether essential (*e.g.*, E1A, E2 and E4) or non-essential (*e.g.*, E3) for replication, may be deleted and replaced with p53.

Particularly preferred are those vectors and virions in which the E1A and E1B regions of the adenovirus vector have been deleted and the p53 expression region introduced in their place, as exemplified by the genome structure of Figure 1.

Techniques for preparing replication defective adenoviruses are well known in the art, as exemplified by Ghosh-Choudhury and Graham (1987); McGrory *et al.* (1988); and Gluzman *et al.* (1982), each incorporated herein by reference. It is also well known that various cell lines may be used to propagate recombinant adenoviruses, so long as they complement any replication defect which may be present. A preferred cell line is the human 293 cell line, but any other cell line that is permissive for replication, *i.e.*, in the preferred case, which expresses E1A and E1B may be employed. Further, the cells can be propagated either on plastic dishes or in suspension culture, in order to obtain virus stocks thereof.

15 20 25
The invention is not limited to E1-lacking virus and E1-expressing cells alone. Indeed, other complementary combinations of viruses and host cells may be employed in connection with the present invention, so long as the p53 vector does not have E1B. Virus lacking functional E2 and E2-expressing cells may be used, as may virus lacking functional E4 and E4-expressing cells, and the like. Where a gene which is not essential for replication is deleted and replaced, such as, for example, the E3 gene, this defect will not need to be specifically complemented by the host cell.

10
Other than the requirement that the adenovirus vectors and virions not have E1B, their nature is not believed to be crucial to the successful practice of the invention. The adenovirus may be of any of the 42 different known serotypes or subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain the conditional replication-defective adenovirus vector for use in the method of the present invention. This is because Adenovirus type 5 is a human adenovirus about which there is significant amount of biochemical and genetic information known, and which has historically been used for most constructions employing adenovirus as a vector.

20
Further related aspects of the invention concern novel p53 DNA segments, or expression vectors, and recombinant host cells which incorporate an adenoviral p53 vector prepared in accordance herewith. The DNA segments of the invention will generally comprise, in the 5'-3' direction of transcription, a cytomegalovirus IE promoter, a structural gene for the wild-type human p53, and an SV40 early polyadenylation signal. The recombinant adenovirus-containing host cell will generally be a eukaryotic or mammalian host cell, such as a 293 cell, or may be a cell with a defect in a p53 gene which has been infected with the adenovirus of the invention.

Other embodiments concern pharmaceutical compositions comprising a recombinant adenovirus which encodes wild type p53, dispersed in a pharmacologically acceptable solution or buffer. Preferred pharmacologically acceptable solutions include neutral saline

solutions buffered with phosphate, lactate, Tris, and the like. Of course, one will desire to purify the adenovirus sufficiently to render it essentially free of undesirable contaminants, such as defective interfering adenovirus particles or endotoxins and other pyrogens such that it will not cause any untoward reactions in the animal or individual receiving the vector construct. A preferred means of purifying the vector involves the use of buoyant density gradients, such as cesium chloride gradient centrifugation.

In still further embodiments, the invention relates to a method for providing p53 functions, or restoring wild-type p53 protein functions, to a cell deficient in wild-type p53. To achieve this, one would contact the cell bearing the p53 mutation with an amount of recombinant adenovirus of the invention effective to express wild-type p53 in the cell. This may be achieved by administering a physiologically effective amount of a pharmaceutical composition comprising the adenovirus to an animal or human subject which harbors cells with defective p53, such as, *e.g.*, cancer cells. Therefore, the present invention also encompasses effective methods for treating human malignancies such as breast and lung cancer.

In another embodiment of the invention the p53 expressing adenovirus is used to prevent malignant and even metastatic growth. In one embodiment the recombinant p53 expressing adenovirus is used to inhibit the uncontrolled growth of cells that have mutations of the p53 gene. In a more preferred embodiment the p53 expressing adenovirus inhibits the tumorigenicity and growth of H358 cells, but any other cell that is an indicator of p53 function may be used.

In a further embodiment the p53 expressing virus is used to prevent orthotopic lung tumor growth when the virus is instilled intratracheally. The Ad5CMV-p53 virus yielded encouraging results in the nude mouse tests. The virus inhibited tumorigenicity of virus-infected H358 cells, a cell that normally produces a significant tumor mass. The virus also prevented orthotopic lung cancer growth when the virus was instilled intratracheally

following the intratracheal inoculation of H226Br cells confirming the *in vitro* effects of Ad5CMV-p53 on the lung cancer cells. The tumorigenicity of the lung cancer cells was inhibited through the treatment by Ad5CMV-p53 but not by the control virus Ad5/RSV/GL2, indicating that the p53 protein has therapeutic efficacy. It will be understood by those skilled in the art that other methods of viral delivery are encompassed by the invention.

While aspects of the invention are exemplified through the use of p53 constructs in connection with restoring normal cell function and for use in cancer treatment, it is proposed that the invention is generally applicable to any situation where one desires to achieve high level expression of a tumor suppressor protein in a target or host cell through the use of recombinant adenovirus. For example, in the context of cancer treatment modalities, a particular example in addition to p53 replacement that is contemplated by the inventors is the introduction of the retinoblastoma gene (*rb*), anti-sense oncogenes (*c-myc* or *c-ras*), and other related genes for human cancer therapy.

It should be pointed out that because the adenovirus vector employed is replication defective, it will not be capable of replicating in the cells, such as cancer cells, that are ultimately infected. Thus, where continued treatment in certain individuals is required, such as at the beginning of therapy, it may be necessary to reintroduce the virus after a certain period, for example, 6 months or a year.

The adenoviral vectors of the present invention will also have utility in embodiments other than those connected directly with gene therapy. Alternative uses include, for example, *in vitro* analyses and mutagenesis studies of various p53 genes, and the recombinant production of proteins for use, for example, in antibody generation or other embodiments. In embodiments other than those connected with human therapy, including all those concerned with further defining the molecular activity of p53, other related viruses may even be employed to deliver p53 to a cell. Those belonging to the herpes family, *e.g.*, herpes

simplex virus (HSV), Epstein-Barr Virus (EBV), cytomegalovirus (CMV) and pseudorabies virus (PRV) would be suitable.

5 A different aspect of the present invention concerns simplified procedures for producing any type of recombinant adenovirus which avoid using the inefficient calcium phosphate transfection and tedious plaque assays. To produce recombinant adenovirus in accordance with the present invention, one would generally introduce an adenovirus plasmid and an expression vector into a suitable host cell by liposome-mediated transfection, and then analyze the cultured host cell for the presence of a cytopathic effect (CPE), which is
10 indicative of homologous recombination and virus production. It is the increase in transfection efficiency of the first step which renders the second and advantageous CPE step possible.

15 A preferred composition for use in the liposome-mediated transfection is DOTAP (N-[1-(2,3-dideoxyloxy) propyl]-N,N,N-trimethyl-ammoniummethysulfate) which is commercially available. CPE is a directly observable phenomenon, which may be assessed using phase contrast microscopy. CPE describes the morphologic features of Adenovirus cytotoxicity that begin with the shrinking of the lytically infected cell and conclude with the formation of a lytic plaque. A particular advantage of this method is that viral propagation is readily
20 determined after a 10 to 14 day incubation. This is a significant improvement over the calcium phosphate-mediated transfection and subsequent plaque assays require at least 14 and usually up to a minimum of 21 days, and frequently up to several weeks before the results can be assessed.

25 In certain embodiments, the method of the invention may be used in connection with adenovirus plasmids which are replication-defective, along with a host cell which complements the defect, as exemplified by E1-lacking plasmids and 293 cells. Adenovirus plasmids which lack functional E1A and E1B and which incorporate a p53 expression region are used herein in working examples of the invention, but any expression region may be

incorporated into a recombinant adenovirus in this manner. The precise methodological aspects may be varied as desired; however, it is contemplated that the use of MEM media will be preferred in certain cases.

5 These new methods may be combined with PCR analysis to confirm the presence of the correctly recombined virus. PCR is well known to those in the art, as disclosed in US Patent No. 4,683,195, incorporated herein by reference. To use PCR in connection with the invention, one would obtain DNA from the supernatant of cells exhibiting a cytopathic effect and analyze the DNA by PCR using two pairs of primers, one expression vector-specific and
10 the other adenoviral genome-specific DNA primers. Vector- or insert-specific DNA is, by definition, a gene segment which is part of the DNA encoding the polypeptide or RNA one ultimately desires to be expressed, as illustrated by p53 DNA expression as mRNA and protein production. Adenovirus genome specific DNA may be any part of the genome that is expressed during the stage of propagation being monitored.

BRIEF DESCRIPTION OF THE DRAWINGS

15 The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

20 Figure 1. Scheme for generation of recombinant p53 adenovirus. The p53 expression cassette was inserted between the Xba I and Cla I sites of pXCJL.1. The p53 expression vector (pEC53) and the recombinant plasmid pJM17 were cotransfected into 293 cells. The transfected cells were maintained in medium until the onset of the cytopathic effect. Identification of newly generated p53 recombinant adenoviruses (Ad5CMV-p53) by PCR

analysis of the DNA using DNA templates prepared from the CPE supernatants treated with Proteinase K and phenol extraction.

Figure 2A shows a map used for the structural analysis of Ad5CMV-p53 DNA. A map of Ad5CMV-p53 genomic DNA, with the locations of the p53 expression cassette, the PCR primers, and the restriction sites. The genome size is about 35.4 kb, divided into 100 maps units (1 m.u. = 0.35 kb). The p53 expression cassette replaced the E1 region (1.3-9.2 m.u.) of the Ad5 genome. Primer 1 is located in the first intron downstream of the human CMV major IE gene promoter. Primer 2 is located in SV40 early polyadenylation signal. Both of the primers, 15-20 bp away from the p53 cDNA insert at both ends, define a 1.40 kb PCR product. Primers 3 and 4 are located at 11 m.u. and 13.4 m.u. of Ad5 genome, respectively, which define a 0.86 kb viral-genome specific PCR product.

Figure 2B shows agarose gel analysis of PCR products. Two pairs of primers that define 1.4-kb (p53) and 0.86-kb (Ad5) DNA fragments were used in each reaction. DNA templates used in each reaction were pEC53 plasmid (lane 1), Ad5/RSV/GL2 DNA (lane 2), no DNA (lane 3), and Ad5CMV-p53 DNA (lane 4). The lane labeled (M) corresponds to molecular weight markers.

Figure 2C shows restriction mapping of Ad5CMV-p53 DNA. CsCl-gradient purified Ad5CMV-p53 DNA samples were digested with no enzyme (U), Hind III (H), Bam HI (B), Eco RI (E), and Cla I (C), respectively, and analyzed on 1% agarose gel. The lanes labeled (M) are molecular weight markers.

Figure 3A, 3B, 3C and 3D, observation of cytopathic effects on 293 by recombinant adenovirus. Figure 3A, 3B, 3C and 3D are a series of phase contrast images (x400) of 293 cells. Figure 3A, 3B, 3C and 3D are four panels of a single page figure. Figure 2A, before transfection; Figure 3B, negative control on day 12 posttransfection; Figure 3C, onset of CPE on day 12 posttransfection; Figure 3D, completion of CPE on day 14 post-transfection.

Figure 4A, 4B, 4C, and 4D, immunohistology of cells infected with recombinant adenoviruses. Figure 4A, 4B, 4C and 4D are a series of immunohistological images of H358 cells. Figure 4A, 4B, 4C and 4D are four panels of a single page figure. Infectivity of Ad5CMV-p53 in H358 cells. H358 cells were infected with Ad5CMV-p53 or Ad5/RSV/GL2 at 50 PFU/cell for 24 h. Medium alone was used as a mock infection. The infected cells were analyzed by immunostainings. Figure 4A is a mock infection probed with anti-p53 antibody. Figure 4B are cells infected with the Ad5/RSV/GL2 control and probed with anti-p53 antibody. Figure 4C are Ad5CMV-p53 infected cells probed with an unrelated antibody (MOPC-21). Figure 4D are cells Ad5CMV-p53 infection probed with anti-p53 antibody. The anti-p53 antibody used was Pab 1801, and the avidin-biotin method was used for staining.

Figure 5A shows a Coomassie-blue stained SDS-PAGE gel comparing the relative level of expression of exogenous p53 in H358 cells. H358 cell samples that were infected with Ad5CMV-p53 or Ad5/RSV/GL2 at 30 PFU/cell were prepared 24 and 72 h after infection. Coomassie blue staining of an SDS-PAGE analysis, showing relative quantities of protein samples loaded. Lanes 1 and 4 contain the samples of the Ad5/RSV/GL2-infected cells. Lanes 2 and 3 contain the samples of the cells infected with two individual stocks of Ad5CMV-p53 at 24 h after infection. Lanes 5 and 6 are the Ad5CMV-p53-infected cell samples collected at 72 h after infection. Lane 7 is mock-infected H358 sample 72 h after infection. Lane M, prestained molecular weight markers in kDa (GIBCO-BRL).

Figure 5B shows a Western blot analysis of the identical lane setting gel as that of the SDS-PAGE in Figure 5A. The relative levels of expression of p53 were analyzed by Western blotting using anti-p53. Primary antibodies used were monoclonal antibodies against p53 protein (PAb 1801, Oncogene Science Inc.) and β -actin (Amersham Inc.). The HRP-conjugated second antibody and ECL developer were from Amersham Inc. viral-infected H358 cells by Western Blotting. Western blot of Figure 5B have an equivalent setup and order to those in Figure 5A.

Figure 6 is a time course of the p53 expression, determined by Western blotting. Multiple dishes of H358 cells were infected with Ad5CMV-p53 at 10 PFU/cell. Cell lysates were prepared at indicated time points after infection. Western blotting was probed with anti-p53 and anti-actin antibodies simultaneously. The lanes designated 'C' represent negative controls. The histogram represents the relative quantities of p53 as determined by a densitometer.

Figure 7A shows the growth curve of virally-infected human lung cancer cells of cell lines H358. Cells were inoculated at 10^5 cells per dish (60 mm) and 6 dishes per cell line. After 24 hours, the cells were infected with Ad5CMV-p53 or Ad5/RSV/GL2 at 10 m.o.i. (Multiplicity of infection, *i.e.*, PFU/cell). After infection cells were counted daily for 6 days. The growth curves represent data obtained from 4 separate studies.

Figure 7B shows the growth curve of virally-infected human lung cancer cells of cell line H322. Cells were inoculated at 10^5 cells per dish (60 mm) and 6 dishes per cell line. After 24 hours, the cells were infected with Ad5CMV-p53 or Ad5/RSV/GL2 at 10 m.o.i. (Multiplicity of infection, *i.e.*, PFU/cell). After infection cells were counted daily for 6 days. The growth curves represent data obtained from 4 separate studies.

Figure 7C shows the growth curve of virally-infected human lung cancer cells of cell line H460. Cells were inoculated at 10^5 cells per dish (60 mm) and 6 dishes per cell line. After 24 hours, the cells were infected with Ad5CMV-p53 or Ad5/RSV/GL2 at 10 m.o.i. (Multiplicity of infection, *i.e.*, PFU/cell). After infection cells were counted daily for 6 days. The growth curves represent data obtained from 4 separate studies.

Figure 8 shows a flow chart of tests of Ad5CMV-p53 in orthotopic lung cancer model. The dosages and schedule of treatment of nude mice innoculated with H226Br cells and viruses are summarized in the flow chart.

Figure 9A, 9B, 9C, and 9D are samples of the lung and mediastinum dissection from treated and control mice. Figure 9A, 9B, 9C, and 9D are four panels of a single figure. The mice were sacrificed at the end of the 6-week posttreatment period. The lung and mediastinum tissues were dissected for evaluation of tumor formation. Figure 9A is a sample of mediastinal block from a normal nude mice; Figure 9B is the mediastinal block sample from the vehicle (PBS)-treated mice; Figure 9C is the mediastinal block sample from the Ad5CMV-p53-treated mice; Figure 9D is the mediastinal block sample from the Ad5/RSV/GL2-treated mice. Arrows indicate the tumor masses.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

A. Molecular Events in Lung Cancer Development

Studies carried out by the present inventors has identified critical molecular events leading to the development and progression of cancer. This enabled the inventors to develop new methods for restoring certain normal protein functions so that the malignant phenotype can be suppressed *in vivo*.

The most common lung cancer histologies (80%) are grouped under the term non-small-cell lung cancer (NSCLC) and include squamous, adenocarcinoma, and large-cell undifferentiated. Many of the current data on the molecular biology of lung cancer come from the study of the more uncommon small-cell lung cancer (SCLC). SCLC can be distinguished from NSCLC by the neuroendocrine features of the cells; SCLC is very responsive to chemotherapy but recurs rapidly after treatment. NSCLC also may serve as a model for other carcinogen-induced epithelial cancers. The approaches and observations developed in this study may be applicable to other types of epithelial cancers.

Abundant evidence has accumulated that the process of malignant transformation is mediated by a genetic paradigm. The major lesions detected in cancer cells occur in

dominant oncogenes and tumor suppressor genes. Dominant oncogenes have alterations in a class of genes called proto-oncogenes, which participate in critical normal cell functions, including signal transduction and transcription. Primary modifications in the dominant oncogenes that confer the ability to transform include point mutations, translocations, rearrangements, and amplification. Tumor suppressor genes appear to require homozygous loss of function, by mutation, deletion, or a combination of these for transformation to occur. Some tumor suppressor genes appear to play a role in the governance of proliferation by regulation of transcription. Modification of the expression of dominant and tumor suppressor oncogenes is likely to influence certain characteristics of cells that contribute to the malignant phenotype.

Despite increasing knowledge of the mechanisms involved in oncogene-mediated transformation, little progress has occurred in developing therapeutic strategies that specifically target oncogenes and their products. Initially, research in this area was focused on dominant oncogenes, as these were the first to be characterized. DNA-mediated gene transfer studies showed acquisition of the malignant phenotype by normal cells following the transfer of DNA from malignant human tumors.

B. p53 and p53 Mutations in Cancer

P53 is currently recognized as a tumor suppressor gene (Montenarh, 1992). High levels have been found in many cells transformed by chemical carcinogenesis, ultraviolet radiation, and several viruses, including SV40. The p53 gene is a frequent target of mutational inactivation in a wide variety of human tumors and is already documented to be the most frequently-mutated gene in common human cancers (Mercer, 1992). It is mutated in over 50% of human NSCLC (Hollestein *et al.*, 1991) and in a wide spectrum of other tumors.

The p53 gene encodes a 375-amino-acid phosphoprotein that can form complexes with host proteins such as large-T antigen and E1B. The protein is found in normal tissues and cells, but at concentrations which are minute by comparison with transformed cells or tumor tissue. Interestingly, wild-type p53 appears to be important in regulating cell growth and division. Overexpression of wild-type p53 has been shown in some cases to be anti-proliferative in human tumor cell lines. Thus p53 can act as a negative regulator of cell growth (Weinberg, 1991) and may directly suppress uncontrolled cell growth or indirectly activate genes that suppress this growth. Thus, absence or inactivation of wild type p53 may contribute to transformation. However, some studies indicate that the presence of mutant p53 may be necessary for full expression of the transforming potential of the gene.

Although wild-type p53 is recognized as a centrally important growth regulator in many cell types, its genetic and biochemical traits appear to have a role as well. Mis-sense mutations are common for the p53 gene and are essential for the transforming ability of the oncogene. A single genetic change prompted by point mutations can create carcinogenic p53. Unlike other oncogenes, however, p53 point mutations are known to occur in at least 30 distinct codons, often creating dominant alleles that produce shifts in cell phenotype without a reduction to homozygosity. Additionally, many of these dominant negative alleles appear to be tolerated in the organism and passed on in the germ line. Various mutant alleles appear to range from minimally dysfunctional to strongly penetrant, dominant negative alleles (Weinberg, 1991).

Casey and colleagues have reported that transfection of DNA encoding wild-type p53 into two human breast cancer cell lines restores growth suppression control in such cells (Casey *et al.*, 1991). A similar effect has also been demonstrated on transfection of wild-type, but not mutant, p53 into human lung cancer cell lines (Takahasi *et al.*, 1992). The p53 appears dominant over the mutant gene and will select against proliferation when transfected into cells with the mutant gene. Normal expression of the transfected p53 does not affect the

growth of cells with endogenous p53. Thus, such constructs might be taken up by normal cells without adverse effects.

It is thus possible that the treatment of p53-associated cancers with wild type p53 may reduce the number of malignant cells. However, studies such as those described above are far from achieving such a goal, not least because DNA transfection cannot be employed to introduce DNA into cancer cells within a patients' body.

C. Gene Therapy Techniques

There have been several experimental approaches to gene therapy proposed to date, but each suffer from their particular drawbacks (Mulligan, 1993). As mentioned above, basic transfection methods exist in which DNA containing the gene of interest is introduced into cells non-biologically, for example, by permeabilizing the cell membrane physically or chemically. Naturally, this approach is limited to cells that can be temporarily removed from the body and can tolerate the cytotoxicity of the treatment, *i.e.* lymphocytes. Liposomes or protein conjugates formed with certain lipids and amphophilic peptides can be used for transfection, but the efficiency of gene integration is still very low, on the order of one integration event per 1,000 to 100,000 cells, and expression of transfected genes is often limited to days in proliferating cells or weeks in non proliferating cells. DNA transfection is clearly, therefore, not a suitable method for cancer treatment.

A second approach capitalizes on the natural ability of viruses to enter cells, bringing their own genetic material with them. Retroviruses have promise as gene delivery vectors due to their ability to integrate their genes into the host genome, transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and of being packaged in special cell-lines. However, three major problems hamper the practical use of retrovirus vectors. First, retroviral infectivity depends on the availability of the viral

receptors on the target surface. Second, retroviruses only integrate efficiently into replicating cells. And finally, retroviruses are difficult to concentrate and purify.

D. Adenovirus Constructs for use in Gene Therapy

Human adenoviruses are double-stranded DNA tumor viruses with genome sizes of approximate 36 kb (Tooza, 1981). As a model system for eukaryotic gene expression, adenoviruses have been widely studied and well characterized, which makes them an attractive system for development of adenovirus as a gene transfer system. This group of viruses is easy to grow and manipulate, and they exhibit a broad host range *in vitro* and *in vivo*. In lytically infected cells, adenoviruses are capable of shutting off host protein synthesis, directing cellular machineries to synthesize large quantities of viral proteins, and producing copious amounts of virus.

The E1 region of the genome includes E1A and E1B which encode proteins responsible for transcription regulation of the viral genome, as well as a few cellular genes. E2 expression, including E2A and E2B, allows synthesis of viral replicative functions, *e.g.* DNA-binding protein, DNA polymerase, and a terminal protein that primes replication. E3 gene products prevent cytolysis by cytotoxic T cells and tumor necrosis factor and appear to be important for viral propagation. Functions associated with the E4 proteins include DNA replication, late gene expression, and host cell shutoff. The late gene products include most of the virion capsid proteins, and these are expressed only after most of the processing of a single primary transcript from the major late promoter has occurred. The major late promoter (MLP) exhibits high efficiency during the late phase of the infection (Stratford-Perricaudet and Perricaudet, 1991a).

As only a small portion of the viral genome appears to be required *in cis* (Tooza, 1981), adenovirus-derived vectors offer excellent potential for the substitution of large DNA fragments when used in connection with cell lines such as 293 cells. Ad5-transformed

human embryonic kidney cell line (Graham, *et al.*, 1977) have been developed to provide the essential viral proteins *in trans*. The inventors thus reasoned that the characteristics of adenoviruses rendered them good candidates for use in targeting cancer cells *in vivo* (Grunhaus & Horwitz, 1992).

5

Particular advantages of an adenovirus system for delivering foreign proteins to a cell include (i) the ability to substitute relatively large pieces of viral DNA by foreign DNA; (ii) the structural stability of recombinant adenoviruses; (iii) the safety of adenoviral administration to humans; and (iv) lack of any known association of adenoviral infection with cancer or malignancies; (v) the ability to obtain high titers of the recombinant virus; and (vi) the high infectivity of Adenovirus.

10

Further advantages of adenovirus vectors over retroviruses include the higher levels of gene expression. Additionally, adenovirus replication is independent of host gene replication, unlike retroviral sequences. Because adenovirus transforming genes in the E1 region can be readily deleted and still provide efficient expression vectors, oncogenic risk from adenovirus vectors is thought to be negligible (Grunhaus & Horwitz, 1992).

15

In general, adenovirus gene transfer systems are based upon recombinant, engineered adenovirus which is rendered replication-incompetent by deletion of a portion of its genome, such as E1, and yet still retains its competency for infection. Relatively large foreign proteins can be expressed when additional deletions are made in the adenovirus genome. For example, adenoviruses deleted in both E1 and E3 regions are capable of carrying up to 10 Kb of foreign DNA and can be grown to high titers in 293 cells (Stratford-Perricaudet and Perricaudet, 1991a). Surprisingly persistent expression of transgenes following adenoviral infection has also been reported.

20

25

Adenovirus-mediated gene transfer has recently been investigated as a means of mediating gene transfer into eukaryotic cells and into whole animals. For example, in

treating mice with the rare recessive genetic disorder ornithine transcarbamylase (OTC) deficiency, it was found that adenoviral constructs could be employed to supply the normal OTC enzyme. Unfortunately, the expression of normal levels of OTC was only achieved in 4 out of 17 instances (Stratford-Perricaudet *et al.*, 1991b). Therefore, the defect was only partially corrected in most of the mice and led to no physiological or phenotypic change. These type of results therefore offer little encouragement for the use of adenoviral vectors in cancer therapy.

Attempts to use adenovirus to transfer the gene for cystic fibrosis transmembrane conductance regulator (CFTR) into the pulmonary epithelium of cotton rats have also been partially successful, although it has not been possible to assess the biological activity of the transferred gene in the epithelium of the animals (Rosenfeld *et al.*, 1992). Again, these studies demonstrated gene transfer and expression of the CFTR protein in lung airway cells but showed no physiologic effect. In the 1991 *Science* article, Rosenfeld *et al.* showed lung expression of α 1-antitrypsin protein but again showed no physiologic effect. In fact, they estimated that the levels of expression that they observed were only about 2% of the level required for protection of the lung in humans, *i.e.*, far below that necessary for a physiologic effect.

The gene for human α ₁-antitrypsin has been introduced into the liver of normal rats by intraportal injection, where it was expressed and resulted in the secretion of the introduced human protein into the plasma of these rats (Jaffe *et al.*, 1992). However, and disappointingly, the levels that were obtained were not high enough to be of therapeutic value.

These type of results do not demonstrate that adenovirus is able to direct the expression of sufficient protein in recombinant cells to achieve a physiologically relevant effect, and they do not, therefore, suggest a usefulness of the adenovirus system for use in connection with cancer therapy. Furthermore, prior to the present invention, it was thought

that p53 could not be incorporated into a packaging cell, such as those used to prepare adenovirus, as it would be toxic. As E1B of adenovirus binds to p53, this was thought to be a further reason why adenovirus and p53 technology could not be combined.

5 E. p53-Adenovirus Constructs and Tumor Suppression

10 The present invention provides cancer gene therapy with a new and more effective tumor suppressor vector. This recombinant virus exploits the advantages of adenoviral vectors, such as high titer, broad target range, efficient transduction, and non-integration in target cells. In one embodiment of the invention, a replication-defective, helper-independent adenovirus is created that expresses wild type p53 (Ad5CMV-p53) under the control of the human cytomegalovirus promoter.

15 Control functions on expression vectors are often provided from viruses when expression is desired in mammalian cells. For example, commonly used promoters are derived from polyoma, adenovirus 2 and simian virus 40 (SV40). The early and late promoters of SV40 virus are particularly useful because both are obtained easily from the virus as a fragment which also contains the SV40 viral origin of replication. Smaller or larger SV40 fragments may also be used provided there is included the approximately 250 bp
20 sequence extending from the *HindIII* site toward the *BglII* site located in the viral origin of replication. Further, it is also possible, and often desirable, to utilize promoter or control sequences normally associated with the included gene sequence, provided such control sequences are compatible with the host cell systems.

25 An origin of replication may be provided by construction of the vector to include an exogenous origin, such as may be derived from SV40 or other viral (*e.g.*, polyoma, adeno, VSV, BPV) source, or may be provided by the host cell chromosomal replication mechanism. If the vector is integrated into the host cell chromosome, the latter is often sufficient.

The design and propagation of the preferred p53 adenovirus is diagramed in Figure 1. In connection with this, an improved protocol has been developed for propagating and identifying recombinant adenovirus (discussed below). After identification, the p53 recombinant adenovirus was structurally confirmed by the PCR analysis, as indicated in Figure 2. After isolation and confirmation of its structure, the p53 adenovirus was used to infect human lung cancer cell line H358, which has a homozygous p53 gene deletion. Western blots showed that the exogenous p53 protein was expressed at a high level (Figure 4 and Figure 5) and peaked at day 3 after infection (Figure 6).

It was also shown in a p53 point mutation cell line H322 that the mutant p53 was down regulated by the expression of the exogenous p53. As an experimental control, a virion (Ad5/RSV/GL2) that had a structural similarity to that of Ad5CMV-p53 was used. This virion contained a luciferase CDNA driven by Rous sarcoma virus LTR promoter in the expression cassette of the virion. Neither p53 expression nor change in actin expression was detected in cells infected by the virion Ad5/RSV/GL2. Growth of the H358 cells infected with Ad5CMV-p53 was greatly inhibited in contrast to that of noninfected cells or the cells infected with the control virion (Figure 7A). Growth of H322 cells was also greatly inhibited by the p53 virion (Figure 7B), while that of human lung cancer H460 cells containing wild-type p53 was less affected (Figure 7C).

Ad5CMV-p53 mediated a strong inhibitory effect on lung cancer cell growth *in vitro*. Growth inhibition was not as evident when the cells were infected with Ad5CMV-p53 at MOI lower than 1 PFU/cell, whereas, at MOI higher than 100 PFU/cell, cytotoxicity could be observed even with control virus Ad5/RSV/GL2. In our studies, the optimal dose for growth rate studies was 10-50 PFU/cell. Within this dose range, cell growth inhibition was attributable to the expressed p53 protein.

Tests in nude mice demonstrated that tumorigenicity of the Ad5CMV-p53-treated H358 cells was greatly inhibited. In a mouse model of orthotopic human lung cancer, the

5 tumorigenic H226Br cells, with a point mutation in p53, were inoculated intratracheally 3 days prior to the virus treatment. Intratracheal instillation of Ad5CMV-p53 prevented tumor formation in this model system suggesting that the modified adenovirus is an efficient vector for mediating transfer and expression of tumor suppressor genes in human cancer cells and that the Ad5CMV-p53 virus may be further developed into a therapeutic agent for use in cancer gene therapy.

10 Ad5CMV-p53 mediated a high level of expression of the p53 gene in human lung cancer cells as demonstrated by Western blot analysis. Exogenous p53 protein was approximately 14 times more abundant than the endogenous wild-type p53 in H460 cells and about two to four times more abundant than the β -actin internal control in H358 cells. The high level of expression may be attributed to (1) highly efficient gene transfer, (2) strong CMV promoter driving the p53 CDNA, and (3) adenoviral E1 enhancer enhancing the p53 CDNA transcription. The duration of p53 expression after infection was more than 15 days in H358 cells. However, there was a rapid decrease in expression after postinfection day 5. PCR analysis of the DNA samples from the infected H358 cells showed a decrease of the viral DNA level with the decreased protein level, indicating the loss of viral DNA during the continuous growth of cancer cells *in vitro*.

20 The decrease in p53 expression may also have resulted from cellular attenuation of the CMV promoter that controls p53 expression, since the phenomenon of host cell-mediated CMV promoter shut off has been reported previously (Dai, *et al.*, 1992). Adenoviral vectors are nonintegrative gene transfer vectors and therefore the duration of gene expression depends upon a number of factors, including the host cells, the genes transferred, and the relevant promoter. Crystal and co-workers showed low level expression of the cystic fibrosis transmembrane conductance regulator gene in cotton rat epithelial cells was detectable 6 weeks after infection (Rosenfeld, *et al.*, 1992). Perricaudet's laboratory demonstrated minimal expression of minidystrophin gene in *mdx* mouse muscle lasted for more than 3 months after infection. The short-term high level expression of the wild-type p53 protein

observed in the present study may have the beneficial effect of reducing possible side effects on normal cells following *in vivo* treatment with Ad5CMV-p53.

The studies disclosed herein indicate that the p53 recombinant adenovirus possesses properties of tumor suppression, which appear to operate by restoring p53 protein function in tumor cells. These results provide support for the use of the Ad5CMV-p53 virion as a therapeutic agent for cancer treatment.

F. Improved Protocol for Propagating and Identifying Recombinant Adenovirus

Recombinant adenovirus as a new gene delivery system has many potential applications in gene therapy and vaccine development. Propagation of recombinant adenovirus is therefore an important molecular biological tool. The existing methods for propagating recombinant adenovirus use calcium phosphate precipitation-mediated transfection into 293 cells and subsequent plaque assays on the transfected cells. The transfection efficiency associated with this method needs to be improved and, also, the procedure could be simplified.

Prior to the present invention, propagation of recombinant adenovirus was conventionally carried out by calcium phosphate-mediated transfection. This procedure involves exposing cells to vector or plasmid DNA in calcium phosphate for several hours prior to a brief shock treatment, *e.g.*, one minute in 15% glycerol. This method suffers from the significant drawback of resulting in only low levels of DNA being incorporated into the cell, *i.e.*, it is a very inefficient means of transfection. Viral propagation was also normally indicated by the appearance of plaques which are observed as clear, round areas around lysed cells indicating cell lysis caused by virus propagation.

The inventors have developed a novel procedure for producing adenovirus which significantly improves the transfection efficiency and also simplifies selection. The inventors

have discovered that a combination of liposome-mediated transfection, such as DOTAP-mediated transfection, with the observation of cytopathic effect (CPE) leads to both improved efficiency and rapid and simplified detection. In the new procedure, liposome DOTAP-mediated gene transfer is used to transduce an expression vector and recombination plasmid into 293 cells. The transfected cells, instead of being overlaid with 0.5% agarose for plaque assays, are then maintained continually in MEM medium for observation of cytopathic effect (CPE).

In two studies using the new method, 2 wells out of a 24-well plate and 3 dishes out of five 60-mm dishes generated CPE at days 10 and 12 after cotransfection, respectively. In contrast, using the calcium-phosphate precipitation method, no recombinant virus was obtained in three trials from the cotransfection with twenty 60-mm dishes in each experiment. Using CAT assays in Hep G2 and HeLa cell lines, DOTAP-mediated transfection resulted in 5 fold higher CAT activity than calcium phosphate transfection.

Elimination of the agarose overlay after cotransfection also simplified the procedure. The endpoint of the study, propagation of virus, becomes much more simple and clear by directly observing the CPE instead of identifying plaques, which is usually unclear and difficult to determine after 10-14 day incubation. Figure 3 shows the cell culture with CPE in comparison with the cell culture without CPE.

The inventors have also developed a rapid technique to determine adenovirus titers using PCR. The direct PCR analysis of DNA samples from the supernatant of the cell cultures with CPE conveniently uses two pairs of primers, one to amplify insert-specific and the other to amplify viral genome-specific sequences. The inventors have shown that adenoviruses released into the cell culture medium are detectable by PCR, thereby allowing one to use as little as about 50 μ L of supernatant to prepare DNA templates.

Identification of the insert-specific and viral genome-specific DNA sequences resulting from PCR amplification may be determined by, for example, analysis of PCR amplified products on agarose gels. Bands corresponding to insert-specific DNA and viral genome-specific DNA, and also the primers, may be identified by comparison with the appropriate standard markers.

Where PCR is employed to amplify insert-specific and viral genome-specific gene products, one will first prepare a primer specific for the sequences to be amplified. Efficient and selective amplification is achieved by employing two primer pairs: one to amplify a defined section of the insert-specific product, and the other to define a segment of the viral genome-specific product. By way of example only, a cassette for expression of p53 has been constructed with a human cytomegalovirus (CMV) promoter and SV40 early polyadenylation signal. The first primer set will include a primer located in the first intron downstream of the human CMV major IE gene promoter while the other primer of the first primer set will be located in SV40 early polyadenylation signal. Ideally, both of these primers are 15 to 20 base pairs away from the cDNA insert which, in the illustrative example, is p53.

A defined PCR product should be selected, for example a 1.40 kb p53 cDNA. As an example, the second set of primers may be located at 11 M.U. and 13.4 M.U. of the Ad5 genome to define a 0.86 kb viral genome specific PCR product.

Primer selection is well known to those of skill in the art. One may construct primers for amplification of selected portions to DNA sequences whose base pair sequence is known. Primers hybridize to DNA and serve as initiation sites for synthesis of a portion of the gene. Nucleotide primers are designed to bind at separate sites on opposing duplex strains thereby defining the intervening sequence as the portion to be amplified. Nucleic acid molecules to be employed as primers will generally include at least a 10 base pair sequence which will be complementary to the DNA segment one desires to amplify. The 10 base pair size is selected as a general lower limit in that sizes smaller than 10 bases may not effectively

hybridize and stabilization may become a problem. Preferably, sizes of 15-20 are utilized and in a preferred aspect of the invention the primer pairs shown in Figure 1 are employed where size is 19 or 20 base pairs.

5 G. Patients and Treatment Protocols

10 The inventors propose that the regional delivery of adenoviral-p53 gene constructs to lung cancer cells in patients with p53-linked cancers, such as unresectable obstructing endobronchial cancers, will be a very efficient method for delivering a therapeutically effective gene to counteract the clinical disease. It is proposed that this approach is a significant improvement on current cancer therapies which rely on attempts to kill or remove the last cancer cell. As tumor cell dormancy is an established phenomenon, this makes effective killing highly unlikely.

15 It is anticipated that the uptake of the adenovirus constructs by NSCLC cells will decrease the rate of proliferation of these cells. This would increase the length of time the affected lung would remain expanded, prevent regrowth of the endobronchial tumor, and prolong the patient's survival.

20 Patients with unresectable endobronchial tumor recurrence that is partially or completely obstructing the airway and that have failed or are unable to receive external beam radiotherapy will be considered for this protocol. Existing therapies for this condition offer only short-term palliation. Most patients have recurred despite external beam radiotherapy. It may be possible to insert a brachytherapy catheter and administer additional radiotherapy. Patients receiving this treatment have a median survival of 6 months. Patients failing brachytherapy would also be eligible to receive gene therapy. [Tumor can be removed from the airway with the laser or biopsy forceps. This can be done in conjunction with injection of the adenoviral constructs thus decreasing the volume that must be injected. The

administration of the viral constructs would not preclude the patient from receiving other palliative therapy if the tumor progresses.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

EXAMPLE 1

Construction of p53 Expression Vector

This example describes the construction of a p53 expression vector. This vector is constructed as indicated and is used to replace the E1 region (1.3-9.2 m.u.) of the Adenovirus strain Ad5 genome and employed to construct the Adenovirus virion described in Example 2.

The p53 expression cassette shown in Figure 1, which contains human cytomegalovirus (CMV) promoter (Boshart, *et al.*, 1985), p53 cDNA, and SV40 early polyadenylation signal, was inserted between the Xba I and Cla I sites of pXCJL1 (provided by Dr. Frank L. Graham, McMaster University, Canada).

The genome size is about 35.4 kb, divided into 100 map units (1 m.u. = 0.35 kb). The p53 expression cassette replaced the E1 region (1.3-9.2 m.u.) of the Ad5 genome.

Primer 1 has the sequence 5'-GGCCCACCCCCTTGGCTTC-3' (SEQ ID NO:1) and is located in the first intron downstream of the human CMV major IE gene promoter (Boshart, *et al.*, 1985). Primer 2 has the sequence 5'-TTGTAACCATTATAAGCTGC-3' (SEQ ID NO:2) and is located in SV40 early polyadenylation signal. Both of the primers, 15-20 bp away from the p53 cDNA insert at both ends, define a 1.40 kb PCR product. Primer 3 has the sequence 5'-TCGTTTCTCAGCAGCTGTTG-3' (SEQ ID NO:3) and primer 4 has the sequence 5'-CATCTGAACTCAAAGCGTGG-3' (SEQ ID NO:4) and are located at 11 m.u. and 13.4 m.u. of the Ad5 genome, respectively, which define a 0.86 kb viral-genome specific PCR product.

EXAMPLE 2

Generation and Propagation of Recombinant p53 Adenovirus

This example describes one method suitable for generating helper-independent recombinant adenoviruses expressing p53. The molecular strategy employed to produce recombinant adenovirus is based upon the fact that, due to the packaging limit of adenovirus, pJM17 cannot form virus on its own. Therefore, homologous recombination between the p53 expression vector plasmid and pJM17 within a transfected cell results in a viable virus that can be packaged only in cells which express the necessary adenoviral proteins.

The method of this example utilizes 293 cells as host cells to propagate viruses that contain substitutions of heterologous DNA expression cassettes at the E1 or E3 regions. This process requires cotransfection of DNA into 293 cells. The transfection largely determines efficiency of viral propagation. The method used for transfection of DNA into 293 cells prior to the present invention was usually calcium-phosphate/DNA coprecipitation (Graham and van der Eb, 1973). However, this method together with the plaque assay is relatively difficult and typically results in low efficiency of viral propagation. As illustrated in this example, transfection and subsequent identification of infected cells were significantly

improved by using liposome-mediated transfection, when identifying the transfected cells by cytopathic effect (CPE).

The 293 cell line was maintained in Dulbecco's modified minimal essential medium supplemented with 10% heat-inactivated horse serum. The p53 expression vector and the plasmid pJM17 (McGrory, *et al.*, 1988) for homologous recombination were cotransfected into 293 cells by DOTAP-mediated transfection according to the manufacture's protocol (Boehringer Mannheim Biochemicals, 1992). This is schematically shown in Figure 1.

The 293 cells (passage 35, 60% confluency) were inoculated 24 hours prior to the transfection in either 60 mm dishes or 24-well plates. The cells in each well were transfected with: 30 μ l DOTAP, 2 μ g of p53 expression vector, and 3 μ g of plasmid pJM17. After transfection cells were fed with the MEM medium every 2-3 days until the onset of CPE.

EXAMPLE 3

Confirming the Identity of Recombinant Adenovirus

This example illustrates a new polymerase chain reaction (PCR) assay for confirming the identity of recombinant virions following cotransfection of the appropriate cell line.

Aliquots of cell culture supernatants (50 to 370 μ l) were collected from the test plates, treated with proteinase K (50 μ g/ml with 0.5% SDS and 20 mM EDTA) at 56°C for 1 hour, extracted with phenol-chloroform, and the nucleic acids were ethanol precipitated. The DNA pellets were resuspended in 20 μ l dH₂O and used as template for PCR amplification. The relative locations of the PCR primers and their sequences are depicted in Figure 1 and are SEQ ID NOS:1, 2, 3 and 4, respectively. The cDNA insert-specific primers define a 1.4 kb PCR product and the viral genome-specific primers define a 0.86 kb PCR product. The PCR

reactions were carried out in a 50 μ l volume containing 4 mM MgCl₂, 50 mM KCl, 0.1% triton X-100, 200 μ M each of dNTPs, 10 mM Tris-Cl (pH 9.0), 2 μ M of each primer, and 1.0 unit of *Taq* polymerase (Promega). The reactions were carried out at 94°C, 0.5 min, 56°C, 0.5 min, and 72°C, 1 min for 30 cycles.

5

In order to simplify the procedure of identification of newly propagated recombinant virus, a direct PCR assay on DNA samples from cell culture supernatant was developed. Aliquots (50 or 370 μ l) of the cell medium supernatant with CPE were treated with proteinase K and phenol/chloroform extraction. After ethanol precipitation, the DNA samples were analyzed using PCR employing two pairs of primers to amplify insert-specific and viral-genome-specific sequences. The PCR primer targets and their sequences are depicted in Figure 1. Primers 1, 2, 3 and 4 are represented by SEQ ID NOS:1, 2, 3 and 4, respectively.

10

As a result, a 1.4 kb cDNA insert and a 0.86 kb viral genome fragment were amplified from the expression vector (positive control) and the DNA samples of the positive cell culture (Figure 2B, lane 1 and 4, respectively). Only the 0.86 kb fragment was amplified from the DNA sample of Ad5/RSV/GL2 virus (negative control, lane 2). No amplified bands appeared from PCR reactions that used either untreated positive cell culture medium supernatant (lane 3).

15

20

These results indicated that adenoviruses released into cell culture medium are detectable by PCR, using as little as 50 μ L of the cell culture medium supernatant for preparing DNA templates. These results will allow development of a quantitative method for using this technique to determine adenovirus titers, traditionally done by plaque assays.

25

The wild-type sequence of the p53 cDNA in the Ad5CMV-p53 virus was confirmed by dideoxy DNA sequencing on the CsCl-gradient-purified viral DNA. The control virus Ad5/RSV/GL2, generated in a similar manner, has a structure similar to that of Ad5CMV-

p53 except a Rous sarcoma viral promoter and luciferase cDNA were used in its expression cassette. The recombinant adenovirus that carries a *E. coli* β -galactosidase gene (LacZ), Ad5CMV-LacZ, also has a structure similar to that of Ad5CMV-p53, and was obtained from Dr. Frank L. Graham.

5

Viral stock, titer, and infection. Individual clones of the Ad5CMV-p53, Ad5/RSV/GL2, and Ad5CMV-LacZ viruses were obtained by plaque-purification according to the method of Graham and Prevec (1991). Single viral clones were propagated in 293 cells. The culture medium of the 293 cells showing the completed cytopathic effect was collected and centrifuged at 1000 x g for 10 min. The pooled supernatants were aliquoted and stored at -20°C as viral stocks. The viral titers were determined by plaque assays (Graham and Prevec, 1991). Infections of the cell lines were carried out by addition of the viral solutions (0.5 ml per 60-mm dish) to cell monolayers and incubation at room temperature for 30 min with brief agitation every 5 min. This was followed by the addition of culture medium and the return of the infected cells to the 37°C incubator.

10

15

The gene transfer efficiency of the recombinant adenoviruses was also evaluated using Ad5CMV-LacZ in a variety of cell lines such as H226Br, H322, H460, HeLa, Hep G2, LM2, and Vero. By X-gal staining, all of the cell lines were stained 97-100% blue after infection with Ad5CMV-LacZ at an MOI of 30 PFU/cell.

20

EXAMPLE 4

Ad5CMV-p53-Directed p53 Gene expression in Human Lung Cancer Cells

5 This example describes the use of recombinant p53 adenovirus to infect human lung cancer cells with a homozygous p53 gene deletion. The results show that growth of these cells and expression of mutant p53 was suppressed, indicating the potential of the Ad5CMV-p53 virion as a useful agent for control of metastatic cells.

10 Immunohistochemistry was performed on infected cell monolayers that were fixed with 3.8% formalin and treated with 3% H₂O₂ in methanol for 5 min. Immunohistochemical analysis was performed using Vectastain Elite kit (Vector, Burlingame, CA). The primary antibody used was anti-p53 antibody PAb 1801 (Oncogene Science, Manhasset, NY); MOPC-21 (Organon Teknika Corp., West Chester, PA) was used as a negative control. The
15 second antibody was an avidin-labeled anti-mouse IgG (Vector). The biotinylated horseradish peroxidase ABC complex reagent was used to detect the antigen-antibody complex. Finally the cells were counterstained with Harris hematoxylin (Sigma) and mounted with Cytoseal 60 (Stephens Scientific, Riverdale, NJ).

20 Immunohistochemical analysis of the infected cell lines was performed to examine the *in situ* expression of p53 expression driven by the CMV promoter of the Ad5CMV-53 virus. In the H358 cell line, which has a homozygous deletion of p53, the p53 gene was transferred with 97-100% efficiency, as detected by immunohistochemical analysis, when the cells were infected with Ad5CMV-p53 at a multiplicity of infection of 30-50 plaque-forming units
25 (PFU)/cell (Figure 4).

The high transfer efficiency of recombinant adenovirus was confirmed by Ad5CMV-LacZ, a virus which carries the LacZ gene transcribed by the human CMV IE promoter. At an MOI of 30-50 PFU/cell, all of the cells examined, including HeLa, Hep G2, LM2, and

the human NSCLC cancer cell lines were 97-100% positive for b-galactosidase activity by X-gal staining. These results indicate that adenoviral vectors are an efficient vehicle for gene transfer into human cancer cells.

5 Western blotting analysis was performed on total cell lysates prepared by lysing
monolayer cells in dishes with SDS-PAGE sample buffer (0.5 ml per 60-mm dish) after
rinsing the cells with phosphate-buffered saline (PBS). For SDS-PAGE analysis lanes were
loaded with cell lysates equivalent to 5×10^4 cells (10-15 ml). The proteins in the gel were
transferred to HybondTM-ECL membrane (Amersham, Arlington Heights, IL). The
10 membranes were blocked with 0.5% dry milk in PBS and probed with the primary
antibodies: mouse anti-human p53 monoclonal antibody PAb 1801 and mouse anti-human β -
actin monoclonal antibody (Amersham), washed and probed with the secondary antibody:
horseradish peroxidase-conjugated rabbit anti-mouse IgG (Pierce Chemical Co., Rockford,
IL). The membranes were developed according to the Amersham's enhanced
15 chemiluminescence protocol. Relative quantities of the exogenous p53 expressed were
determined by densitometer (Molecular Dynamics Inc., Sunnyvale, CA).

Western blots showed the exogenous p53 protein was expressed at a high level
(Figure 5A lanes 2,3 and 5,6). The protein peaked at day 3 after infection (Figure 6, insert,
0.5 days to 3 days). As a control, a virion with a structure similar to the recombinant
20 Ad5CMV-p53 of Example 1 was constructed. This virion contains a luciferase cDNA driven
by Rous Sarcoma Virus LTR promoter in the expression cassette of the virion. Neither p53
expression nor change in actin expression was detected in the cells infected by the virion
Ad5/RSV/GL2.

25 The recombinant p53 adenovirus was used to infect three human lungs NSCLC cell
lines: cell line H358, which has a homozygous deletion of the p53 gene, cell line H322,
which has a point mutation of the p53 gene at codon 248 (G to T), and cell line H460, which

has a wild-type p53 gene. The growth rate of human NSCLC cells was determined following the inoculation of H322 and H460 (1×10^5) or H358 (2×10^5) in 60-mm culture dishes 24 h before viral infection. The cells were infected with the viruses at a multiplicity of infection (MOI) of 10 PFU/cell. Culture medium was used for the mock infection control. Triplet cultures of each cell line with different treatments were counted daily for days 1-6 after infection.

Growth of the H358 cells infected with Ad5CMV-p53 was greatly inhibited in contrast to that of noninfected cells or the cells infected with the control virion (Figure 7A). Growth of H322 cells was also greatly inhibited by the p53 virion (Figure 7B), while that of human lung cancer H460 cells containing wild type p53 was affected to a lesser degree (Figure 7C). Growth of the Ad5CMV-p53 virus-infected H358 cells was inhibited 79%, whereas that of noninfected cells or the cells infected with the control virus were not inhibited. Growth of cell line H322, which has a point mutation in p53, was inhibited 72% by Ad5CMV-p53, while that of cell line H460 containing wild-type p53 was less affected (28% inhibition).

The results indicate that the p53 recombinant adenovirus possesses properties of tumor suppression, working through restoration of the p53 protein function in tumor cells.

EXAMPLE 5

Ad5CMV-p53 in the Treatment of p53 Deficient Cells

The present example concerns the use of recombinant p53 adenovirus to restore growth suppression of tumor cells *in vitro* and thus to treat the malignant or metastatic growth of cells. It describes some of the ways in which the present invention is envisioned to be of use in the treatment of cancer via adenovirus-mediated gene therapy.

H358 cells were infected with Ad5CMV-p53 and Ad5/RSV/GL2 at a MOI of 10 PFU/cell. An equal amount of cells were treated with medium as a mock infection. Twenty-four hours after infection, the treated cells were harvested and rinsed twice with PBS. For each treatment, three million (3×10^6) cells in a volume of 0.1 ml were injected s.c. to each nude mouse (Harlan Co., Houston, TX). Five mice were used for each treatment. Mice were irradiated (300 cGy, ^{60}Co) before injection and examined weekly after injection. Tumor formation was evaluated at the end of a 6-week period and tumor volume was calculated by assuming a spherical shape with the average tumor diameter calculated as the square root of the product of cross-sectional diameters.

To determine the inhibitory effect on tumorigenicity mediated by Ad5CMV-p53 nude mice were injected s.c. with H358 cells (a human NSCLC-type cell) to induce neoplastic growth. Each mouse received one injection of cells that had been infected with Ad5CMV-p53 or Ad5/RSV/GL2 at 10 PFU/cell for 24 h. H358 cells treated with medium alone were used as mock-infected controls. Tumors, first palpable at postinjection day 14, were induced only by the mock- or control virus-infected cells as demonstrated in Table I:

Table I. Effect of Ad5CMV-p53 on tumorigenicity of H358 in nude mice^a

Treatment	No. of Tumors/ No. of Mice (%)	Mean Volume (mm ³ \pm SD)
Medium	4/5 (80)	37 \pm 12
Ad5/RSV/GL2	3/4 (75)	30 \pm 14
Ad5CMV-p53	0/4 (0)	-

^a The treated H358 cells were injected s.c. at 2×10^6 cells/mouse. Tumor sizes were determined at the end of a 6-week period.

As shown in Table 1 mice that received Ad5CMV-p53-treated cells did not develop tumors. The tumors at the end of a 6-week period were 4-10 mm in diameter. This study was initiated with five mice per group; one mouse each in the Ad5CMV-p53 or Ad5/RSV/GL2 group failed to complete the study. The early deaths were presumably due to nosocomial infection.

EXAMPLE 6

Ad5CMV-p53 in the Treatment of Lung Cancer

The present example concerns the use of recombinant p53 adenovirus to restore growth suppression of tumor cells *in vivo* and thus to treat cancers in animals. It describes some of the ways in which the present invention is envisioned to be of use in the treatment of cancer via adenovirus-mediated gene therapy.

The efficacy of Ad5CMV-p53 in inhibiting tumorigenicity was further evaluated in the mouse model of orthotopic human lung cancer. Since H358 and H322 cells did not produce tumors in this model, cell line H226Br was used. This cell line has a squamous lung cancer origin and metastasized from lung to brain. H226br has a point mutation (ATC to GTC) at exon 7, codon 254, of the p53 gene and is tumorigenic in mice.

The procedure for tests in the mouse model of orthotopic human lung cancer has been previously described (Georges, et al., 1993). Briefly, nude mice treated with radiation (300 cGy, ^{60}Co) were inoculated with H226Br cells by intratracheal instillation. Each mouse received 2×10^6 cells in a volume of 0.1 ml PBS. Three days after inoculation, 10 mice per group were treated with 0.1 ml of viruses or vehicle (PBS) by intratracheal instillation once a day for two days. The virus dosage used was 5×10^7 Ad5CMV-p53 or Ad5/RSV/GL2 per mouse. The mice were euthanized at the end of a 6-week period. Tumor formation was

evaluated by dissecting the lung and mediastinum tissues and measuring the tumor size. The tumors were confirmed by histologic analysis of the sections of the tumor mass.

5 The irradiated nude mice were inoculated with 2×10^6 H226Br cells/mouse by intratracheal instillation. Three days after inoculation, each of the mice (8-10 mice per group) were treated with 0.1 ml of either Ad5CMV-p53 or Ad5/RSV/GL2 or vehicle (PBS) by intratracheal instillation once a day for two days. The virus dosage used was 5×10^7 PFU/mouse. Tumor formation was evaluated at the end of a 6-week period by dissecting the lung and mediastinum tissues and measuring the tumor size. A flow chart of the procedure is depicted in Figure 7, with representative samples of dissection demonstrated in Figure 8. 10 The detected tumors were confirmed by histologic analysis. The data of tumor measurements are summarized in Table II:

Table II. Effect of Ad5CMV-p53 on tumorigenicity of H226Br in mouse model of orthotopic human lung cancer^a

Treatment	No. mice with Tumors/ Total Mice (%)	Mean Volume (mm ³ ± SD)
Vehicle	7/10 (70)	30 ± 8.4
Ad5/RSV/GL2	8/10 (80)	25 ± 6.9
Ad5CMV-p53	2/8 (25)	8 ± 3.3 ^b

^a Mice were inoculated with 2×10^6 H226Br cells/mouse intratracheally. On the 3rd day postinoculation, the mice were given either vehicle or viruses (5×10^7 each in 0.1 ml) intratracheally once a day for 2 days. Tumor formation was evaluated at the end of a 6-week period.

^b $p < 0.05$ by two-way analysis of variance when compared to the groups receiving vehicle (PBS) or virus control.

Only 25% of the Ad5CMV-p53-treated mice formed tumors, whereas in the vehicle or Ad5/RSV/GL2 control group, 70-80% of the treated mice formed tumors. The average tumor size of the Ad5CMV-p53 group was significantly smaller than those of the control groups. These results indicate that Ad5CMV-p53 can prevent H226Br from forming tumors in the mouse model of orthotopic human lung cancer.

EXAMPLE 7

Ad5CMV-p53 in Treatment Regimens

Naturally, animal models will be employed as part of the pre-clinical trials, as described herein in Examples 5 and 6. Thereafter, patients for whom the medical indication for adenovirus-mediated gene transfer treatment has been established may be tested for the presence of antibodies directed against adenovirus. If antibodies are present and the patient has a history of allergy to either pharmacological or naturally occurring substances, application of a test dose of on the order of 10^3 to 10^6 recombinant adenovirus under close clinical observation would be indicated.

For the treatment of cancer using Ad5CMV-p53, recombinant adenovirus expressing p53 under the control of suitable promoter/enhancer elements, such as the CMV promoter, would be prepared and purified according to a method that would be acceptable to the Food and Drug Administration (FDA) for administration to human subjects. Such methods include, but are not limited to, cesium chloride density gradient centrifugation, followed by testing for efficacy and purity.

Two basic methods are considered to be suitable for p53 adenovirus treatment methods, a direct or local administration and a more general administration. The present methods are suitable for treating any of the variety of different cancers known to be connected with p53 mutations. In regard to general administration, a simple intravenous injection of adenovirus has been shown to be sufficient to result in viral infection of tissues at sites distant from the injection (Stratford-Perricaudet *et al.*, 1991b), and is thus suitable for the treatment of all p53-linked malignancies. The virus may be administered to patients by means of intravenous administration in any pharmacologically acceptable solution, or as an infusion over a period of time. Generally speaking, it is believed that the effective number of functional virus particles to be administered would range from 1×10^{10} to 5×10^{12} .

Also, particularly where lung cancer is concerned, more direct physical targeting of the recombinant adenovirus could be employed if desired, in an analogous manner to the intratracheal administration of the cystic fibrosis transmembrane conductance regulator (Rosenfeld *et al.*, 1992). This would result in the delivery of recombinant p53 adenovirus closer to the site of the target cells.

In more detail, preferred treatment protocols may be developed along the following lines. Patients may first undergo bronchoscopy to assess the degree of obstruction. As much gross tumor as possible should be resected endoscopically. Patients should preferably undergo bronchoscopy under topical or general anesthesia. A Stifcor[™] transbronchial aspiration needle (21g) will be passed through the biopsy channel of the bronchoscope. The residual tumor site would then be injected with the p53 adenovirus in a small volume such as about 10 ml or less.

In any event, since the adenovirus employed will be replication incompetent, no deleterious effect of the virus itself on subject health is anticipated. However, patients would remain hospitalized during the treatment for at least 48 hours to monitor acute and delayed adverse reactions. Safety-related concerns of the use of replication deficient adenovirus as a gene transfer vehicle in humans have been addressed in the past (Rosenfeld *et al.*, 1992; Jaffe *et al.*, 1992), but the dose of adenovirus to be administered should be appropriately monitored so as to further minimize the chance of untoward side effects.

There are various criteria that one should consider as presenting the existence of a need for response or the existence of toxicity. To assist in determining the existence of toxicity, the tumor bed should be photographed prior to a course of therapy. The longest diameter and its perpendicular will be measured. Size will be reported as the product of the diameters. From these data, one can calculate from these numbers the rate of regrowth of the tumor.

The time to progression can also be measured from the first observation with reduction in tumor bulk until there is evidence of progressive disease. Progressive Disease is defined as an increase of $\geq 25\%$ in the sum of the products of the diameters of the measured lesion. Patients must have received at least two courses of therapy before a designation of progression is made. The survival of patients will be measured from entry into protocol.

Follow-up examinations would include all those routinely employed in cancer therapy, including monitoring clinical signs and taking biopsies for standard and molecular biological analysis in which the pattern of expression of various p53 genes could be assessed. This would also supply information about the number of cells that have taken up the transferred gene and about the relative promoter strength *in vivo*. Based on the data obtained adjustments to the treatment may be desirable. These adjustments might include adenovirus constructs that use different promoters or a change in the number of pfu injected to ensure a infection of more, or all, tumor cells without unphysiological overexpression of the recombinant genes.

It is contemplated that the expression of exogenous genes transferred *in vivo* by adenovirus can persist for extended periods of time. Therapeutically effective long-term expression of virally transferred exogenous genes will have to be addressed on a case by case basis. Marker genes are limited in their usefulness to assess therapeutically relevant persistence of gene expression as the expression levels required for the amelioration of any given genetic disorder might differ considerably from the level required to completely cure another disease.

*

*

*

While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims. All claimed matter and methods can be made and executed without undue experimentation.

REFERENCES

The following references to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

Bargonetti, *et al.* (1991) *Cell* 65:1083-1091.

Boehringer Mannheim Biochemicals (1992). DOTAP for high efficiency transfections, *BMBiochemica* 9(1):17.

Boshart, M. *et al.* (1985). A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. *Cell*, 41:521-530.

Bishop (1987) *Science* 235:305-311.

Casey, G. Lo-Hueh, M., Lopez, M. E., Vogelstein, B., and Stanbridge, E. J. (1991). Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. *Oncogene* 6:1791-1797.

Dai, *et al.* (1992) *Proc. Natl. Acad. Sci.* 89:10892-10895.

Fields *et al.* (1990) *Science* 249:1046-1049.

Georges *et al.* (1993) *Cancer Res* 53:1743-1746.

Ghosh-Choudhury and Graham (1982) *Biochem. Biophys. Res. Comm.* 147:964-973.

Gluzman *et al.*, (1982) in *Eukaryotic Viral Vectors* (Gluzman, Y., Ed.) pp. 187-192, Cold Spring Harbor Press, Cold Spring Harbor, New York.

Graham, F.L. and A.J. van der Eb. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology* 52:456-467.

Graham, F.L., J. Smiley, W.C. Russell and R. Nairn (1977). Characteristics of a human cell line transformed by DNA from human adenovirus type 5. *J. Gen Virol.* 36:59-72.

Grunhaus, A. and Horwitz, M.S. (1992). Adenoviruses as cloning vectors. *Semin. Virology* 3:237-2542.

Hollstein, M., Sidransky, D., Vogelstein, B., and Harris, C. (1991). p53 mutations in human cancers. *Science* 253:49-53.

Jaffe *et al.*, (1992) *Nature Genetics* 1:372-378.

Le Gal *et al.*, (1993) *Science* 259:988-990.

McGrory, W.J. *et al.* (1988). A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5. *Virology* 163:614-617.

Mercer, W.E. (1992). Cell cycle regulation and the p53 tumor suppressor protein. *Critic. Rev. Eukar. Gene Express.* 2:251-263.

Mietz, *et al.* (1992) *EMBO* 11:5013-5020.

Montenarh, M. (1992). Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53. *Critic. Rev. Onco.* 3:233-256.

Mulligan, (1993), *Science* 260:926.

Ragot *et al.*, (1993) *Nature*, 361:647-650.

Rosenfeld *et al.*, (1991) *Science*, 232:431-434.

Rosenfeld *et al.*, (1992) *Cell* 68:143-155.

Shaw, *et al.*, (1992) 89:4495-4499.

Spandidos, *et al.* (1989), *J. Pathol.*, 157:1-10.

Stratford-Perricaudet, L. and M. Perricaudet. (1991a). Gene transfer into animals: the promise of adenovirus. p. 51-61, *In* O. Cohen-Haguenauer and M. Boiron (Eds.), *Human Gene Transfer*, Editions John Libbey Eurotext, France.

Stratford-Perricaudet *et al.*, (1991b) *Hum. Gene. Ther.* 1:241-256

Takahashi, T., Carbone, D., Takahashi, T., Nau, M.M., Hida, T., Linnoila, I., Ueda, R., and Minna, J. D. (1992). Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. 1992. *Cancer Res.* 52:2340-2342.

Tooza, J. (1981). *Molecular biology of DNA Tumor viruses*, 2nd ed. Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.

Travali, *et al.* (1990), *FASEB*, 4:3209-3214.

Yonish, *et al.* (1991), *Nature* 352:345-347.

5 Weinberg, R.A. (1991). Tumor suppressor gene. *Science* 254:1138-1145.

Wilcock, *et al.* (1991) *Nature* 349:429-431.

Zakut-Houri et al. (1985), *EMBO J.*, 4:1251-1255.

10

Zhang, *et al.* (1993) *BioTechniques* in press.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) Applicant: University of Texas System

(ii) Title of Invention: **RECOMBINANT P53 ADENOVIRUS METHODS AND COMPOSITIONS**

(iii) Number of Sequences: 4

(iv) Correspondence Address:

(A) Addressee: Arnold, White & Durkee
(B) Street: P.O. Box 4433
(C) City: Houston
(D) State: Texas
(E) Country: USA
(F) Zip: 77210

(v) Computer Readable Form:

(A) Medium Type: Floppy Disk
(B) Computer: IBM PC Compatible
(C) Operating System: PC-DOS/MS-DOS
(D) Software: ASCII-DOS

(vi) Current Application Data:

(A) Application Number: Unknown
(B) Filing Date: Unknown
(C) Classification: Unknown

(vii) Attorney/Agent Information:

(A) Name: Barbara S. Kitchell
(B) Registration Number: 33,928
(C) Reference/Docket Number: UTSC:350

(viii) Telecommunication Information:

- (A) Telephone: (512) 320-7200
(B) Telefax: (512) 474-7577

(2) INFORMATION FOR SEQ ID NO: 1:

(i) Sequence characteristics:

- (A) Length: 20
(B) Type: Nucleic acid
(C) Strandedness: Single
(D) Topology: Linear

(ii) Molecule Type:

(iii) Sequence Description: SEQ ID NO: 1:

GGCCCACCC CCTTGGCTTC

20

(3) INFORMATION FOR SEQ ID NO: 2:

(i) Sequence characteristics:

- (A) Length: 20
(B) Type: Nucleic acid
(C) Strandedness: Single
(D) Topology: Linear

(ii) Molecule Type:

(iii) Sequence Description: SEQ ID NO: 2:

TTGTAACCAT TATAAGCTGC

20

(4) INFORMATION FOR SEQ ID NO: 3:

(i) Sequence characteristics:

- (A) Length: 20
(B) Type: Nucleic acid
(C) Strandedness: Single
(D) Topology: Linear

(ii) Molecule Type:

(iii) Sequence Description: SEQ ID NO: 3:

TCGTTTCTCA GCAGCTGTTG

20

5 (5) INFORMATION FOR SEQ ID NO: 4:

(i) Sequence characteristics:

(A) Length: 20

(B) Type: Nucleic acid

(C) Strandedness: Single

(D) Topology: Linear

(ii) Molecule Type:

(iii) Sequence Description: SEQ ID NO: 4:

CATCTGAACT CAAAGCGTGG

20

20
60
120
180
240
300
360
420
480
540
600
660
720
780
840
900
960
1020
1080
1140
1200
1260
1320
1380
1440
1500
1560
1620
1680
1740
1800
1860
1920
1980
2040
2100
2160
2220
2280
2340
2400
2460
2520
2580
2640
2700
2760
2820
2880
2940
3000
3060
3120
3180
3240
3300
3360
3420
3480
3540
3600
3660
3720
3780
3840
3900
3960
4020
4080
4140
4200
4260
4320
4380
4440
4500
4560
4620
4680
4740
4800
4860
4920
4980
5040
5100
5160
5220
5280
5340
5400
5460
5520
5580
5640
5700
5760
5820
5880
5940
6000
6060
6120
6180
6240
6300
6360
6420
6480
6540
6600
6660
6720
6780
6840
6900
6960
7020
7080
7140
7200
7260
7320
7380
7440
7500
7560
7620
7680
7740
7800
7860
7920
7980
8040
8100
8160
8220
8280
8340
8400
8460
8520
8580
8640
8700
8760
8820
8880
8940
9000
9060
9120
9180
9240
9300
9360
9420
9480
9540
9600
9660
9720
9780
9840
9900
9960
10020
10080
10140
10200
10260
10320
10380
10440
10500
10560
10620
10680
10740
10800
10860
10920
10980
11040
11100
11160
11220
11280
11340
11400
11460
11520
11580
11640
11700
11760
11820
11880
11940
12000
12060
12120
12180
12240
12300
12360
12420
12480
12540
12600
12660
12720
12780
12840
12900
12960
13020
13080
13140
13200
13260
13320
13380
13440
13500
13560
13620
13680
13740
13800
13860
13920
13980
14040
14100
14160
14220
14280
14340
14400
14460
14520
14580
14640
14700
14760
14820
14880
14940
15000
15060
15120
15180
15240
15300
15360
15420
15480
15540
15600
15660
15720
15780
15840
15900
15960
16020
16080
16140
16200
16260
16320
16380
16440
16500
16560
16620
16680
16740
16800
16860
16920
16980
17040
17100
17160
17220
17280
17340
17400
17460
17520
17580
17640
17700
17760
17820
17880
17940
18000
18060
18120
18180
18240
18300
18360
18420
18480
18540
18600
18660
18720
18780
18840
18900
18960
19020
19080
19140
19200
19260
19320
19380
19440
19500
19560
19620
19680
19740
19800
19860
19920
19980
20040
20100
20160
20220
20280
20340
20400
20460
20520
20580
20640
20700
20760
20820
20880
20940
21000
21060
21120
21180
21240
21300
21360
21420
21480
21540
21600
21660
21720
21780
21840
21900
21960
22020
22080
22140
22200
22260
22320
22380
22440
22500
22560
22620
22680
22740
22800
22860
22920
22980
23040
23100
23160
23220
23280
23340
23400
23460
23520
23580
23640
23700
23760
23820
23880
23940
24000
24060
24120
24180
24240
24300
24360
24420
24480
24540
24600
24660
24720
24780
24840
24900
24960
25020
25080
25140
25200
25260
25320
25380
25440
25500
25560
25620
25680
25740
25800
25860
25920
25980
26040
26100
26160
26220
26280
26340
26400
26460
26520
26580
26640
26700
26760
26820
26880
26940
27000
27060
27120
27180
27240
27300
27360
27420
27480
27540
27600
27660
27720
27780
27840
27900
27960
28020
28080
28140
28200
28260
28320
28380
28440
28500
28560
28620
28680
28740
28800
28860
28920
28980
29040
29100
29160
29220
29280
29340
29400
29460
29520
29580
29640
29700
29760
29820
29880
29940
30000
30060
30120
30180
30240
30300
30360
30420
30480
30540
30600
30660
30720
30780
30840
30900
30960
31020
31080
31140
31200
31260
31320
31380
31440
31500
31560
31620
31680
31740
31800
31860
31920
31980
32040
32100
32160
32220
32280
32340
32400
32460
32520
32580
32640
32700
32760
32820
32880
32940
33000
33060
33120
33180
33240
33300
33360
33420
33480
33540
33600
33660
33720
33780
33840
33900
33960
34020
34080
34140
34200
34260
34320
34380
34440
34500
34560
34620
34680
34740
34800
34860
34920
34980
35040
35100
35160
35220
35280
35340
35400
35460
35520
35580
35640
35700
35760
35820
35880
35940
36000
36060
36120
36180
36240
36300
36360
36420
36480
36540
36600
36660
36720
36780
36840
36900
36960
37020
37080
37140
37200
37260
37320
37380
37440
37500
37560
37620
37680
37740
37800
37860
37920
37980
38040
38100
38160
38220
38280
38340
38400
38460
38520
38580
38640
38700
38760
38820
38880
38940
39000
39060
39120
39180
39240
39300
39360
39420
39480
39540
39600
39660
39720
39780
39840
39900
39960
40020
40080
40140
40200
40260
40320
40380
40440
40500
40560
40620
40680
40740
40800
40860
40920
40980
41040
41100
41160
41220
41280
41340
41400
41460
41520
41580
41640
41700
41760
41820
41880
41940
42000
42060
42120
42180
42240
42300
42360
42420
42480
42540
42600
42660
42720
42780
42840
42900
42960
43020
43080
43140
43200
43260
43320
43380
43440
43500
43560
43620
43680
43740
43800
43860
43920
43980
44040
44100
44160
44220
44280
44340
44400
44460
44520
44580
44640
44700
44760
44820
44880
44940
45000
45060
45120
45180
45240
45300
45360
45420
45480
45540
45600
45660
45720
45780
45840
45900
45960
46020
46080
46140
46200
46260
46320
46380
46440
46500
46560
46620
46680
46740
46800
46860
46920
46980
47040
47100
47160
47220
47280
47340
47400
47460
47520
47580
47640
47700
47760
47820
47880
47940
48000
48060
48120
48180
48240
48300
48360
48420
48480
48540
48600
48660
48720
48780
48840
48900
48960
49020
49080
49140
49200
49260
49320
49380
49440
49500
49560
49620
49680
49740
49800
49860
49920
49980
50040
50100
50160
50220
50280
50340
50400
50460
50520
50580
50640
50700
50760
50820
50880
50940
51000
51060
51120
51180
51240
51300
51360
51420
51480
51540
51600
51660
51720
51780
51840
51900
51960
52020
52080
52140
52200
52260
52320
52380
52440
52500
52560
52620
52680
52740
52800
52860
52920
52980
53040
53100
53160
53220
53280
53340
53400
53460
53520
53580
53640
53700
53760
53820
53880
53940
54000
54060
54120
54180
54240
54300
54360
54420
54480
54540
54600
54660
54720
54780
54840
54900
54960
55020
55080
55140
55200
55260
55320
55380
55440
55500
55560
55620
55680
55740
55800
55860
55920
55980
56040
56100
56160
56220
56280
56340
56400
56460
56520
56580
56640
56700
56760
56820
56880
56940
57000
57060
57120
57180
57240
57300
57360
57420
57480
57540
57600
57660
57720
57780
57840
57900
57960
58020
58080
58140
58200
58260
58320
58380
58440
58500
58560
58620
58680
58740
58800
58860
58920
58980
59040
59100
59160
59220
59280
59340
59400
59460
59520
59580
59640
59700
59760
59820
59880
59940
60000
60060
60120
60180
60240
60300
60360
60420
60480
60540
60600
60660
60720
60780
60840
60900
60960
61020
61080
61140
61200
61260
61320
61380
61440
61500
61560
61620
61680
61740
61800
61860
61920
61980
62040
62100
62160
62220
62280
62340
62400
62460
62520
62580
62640
62700
62760
62820
62880
62940
63000
63060
63120
63180
63240
63300
63360
63420
63480
63540
63600
63660
63720
63780
63840
63900
63960
64020
64080
64140
64200
64260
64320
64380
64440
64500
64560
64620
64680
64740
64800
64860
64920
64980
65040
65100
65160
65220
65280
65340
65400
65460
65520
65580
65640
65700
65760
65820
65880
65940
66000
66060
66120
66180
66240
66300
66360
66420
66480
66540
66600
66660
66720
66780
66840
66900
66960
67020
67080
67140
67200
67260
67320
67380
67440
67500
67560
67620
67680
67740
67800
67860
67920
67980
68040
68100
68160
68220
68280
68340
68400
68460
68520
68580
68640
68700
68760
68820
68880
68940
69000
69060
69120
69180
69240
69300
69360
69420
69480
69540
69600
69660
69720
69780
69840
69900
69960
70020
70080
70140
70200
70260
70320
70380
70440
70500
70560
70620
70680
70740
70800
70860
70920
70980
71040
71100
71160
71220
71280
71340
71400
71460
71520
71580
71640
71700
71760
71820
71880
71940
72000
72060
72120
72180
72240
72300
72360
72420
72480
72540
72600
72660
72720
72780
72840
72900
72960
73020
73080
73140
73200
73260
73320
73380
73440
73500
73560
73620
73680
73740
73800
73860
73920
73980
74040
74100
74160
74220
74280
74340
74400
74460
74520
74580
74640
74700
74760
74820
74880
74940
75000
75060
75120
75180
75240
75300
75360
75420
75480
75540
75600
75660
75720
75780
75840
75900
75960
76020
76080
76140
76200
76260
76320
76380
76440
76500
76560
76620
76680
76740
76800
76860
76920
76980
77040
77100
77160
77220
77280
77340
77400
77460
77520
77580
77640
77700
77760
77820
77880
77940
78000
78060
78120
78180
78240
78300
78360
78420
78480
78540
78600
78660
78720
78780
78840
78900
78960
79020
79080
79140
79200
79260
79320
79380
79440
79500
79560
79620
79680
79740
79800
79860
79920
79980
80040
80100
80160
80220
80280
80340
80400
80460
80520
80580
80640
80700
80760
80820
80880
80940
81000
81060
81120
81180
81240
81300
81360
81420
81480
81540
81600
81660
81720
81780
81840
81900
81960
82020
82080
82140
82200
82260
82320
82380
82440
82500
82560
82620
82680
82740
82800
82860
82920
82980
83040
83100
83160
83220
83280
83340
83400
83460
83520
83580
83640
83700
83760
83820
83880
83940
84000
84060
84120
84180
84240
84300
84360
84420
84480
84540
84600
84660
84720
84780
84840
84900
84960
85020
85080
85140
85200
85260
85320
85380
85440
85500
85560
85620
85680
85740
85800
85860
85920
85980
86040
86100
86160
86220
86280
86340
86400
86460
86520
86580
86640
86700
86760
86820
86880
86940
87000
87060
87120
87180
87240
87300
87360
87420
87480
87540
87600
87660
87720
87780
87840
87900
87960
88020
88080
88140
88200
88260
88320
88380
88440
88500
88560
88620
88680
88740
88800
88860
88920
88980
89040
89100
89160
89220
89280
89340
89400
89460
89520
89580
89640
89700
89760
89820
89880
89940
90000
90060
90120
90180
90240
90300
90360
90420
90480
90540
90600
90660
90720
90780
90840
90900
90960
91020
91080
91140
91200
91260
91320
91380
91440
91500
91560
91620
91680
91740
91800
91860
91920
91980
92040
92100
92160
92220
92280
92340
92400
92460
92520
92580
92640
92700
92760
92820
92880
92940
93000
93060
93120
93180
93240
93300
93360
93420
93480
93540
93600
93660
93720
93780
93840
93900
93960
94020
94080
94140
94200
94260
94320
94380
94440
94500
94560
94620
94680
94740
94800
94860
94920
94980
95040
95100
95160
95220
95280
95340
95400
95460
95520
95580
95640
95700
95760
95820
95880
95940
96000
96060
96120
96180
96240
96300
96360
96420
96480
96540
96600
96660
96720
96780
96840
96900
96960
97020
97080
97140
97200
97260
97320
97380
97440
97500
97560
97620
97680
97740
97800
97860
97920
97980
98040
98100
98160
98220
98280
98340
98400
98460
98520
98580
98640
98700
98760
98820
98880
98940
99000
99060
99120
99180
99240
99300
99360
99420
99480
99540
99600
99660
99720
99780
99840
99900
99960
100020
100080
100140
100200
100260
100320
100380
100440
100500
100560
100620
100680
100740
100800
100860
100920
100980
101040
101100
101160
101220
101280
101340
101400
101460
101520
101580
101640
101700
101760
101820
101880
101940
102000
102060
102120
102180
102240
102300
102360
102420
102480
102540
102600
1

WHAT IS CLAIMED IS:

1. A recombinant adenovirus which carries an adenovirus vector construct comprising an
5 expression region encoding p53, the vector capable of expressing p53 in human malignant
cells.
2. The recombinant adenovirus of claim 1, wherein the vector construct comprises a p53
10 expression region positioned under the control of the cytomegalovirus IE promoter.
3. The recombinant adenovirus of claim 2, wherein the vector construct comprises a p53
15 expression region, the cytomegalovirus IE promoter and the SV40 early polyadenylation
signal.
4. The recombinant adenovirus of claim 1, wherein a gene essential for adenovirus
20 replication is deleted from the vector construct and the p53 expression region is introduced in
its place.
5. The recombinant adenovirus of claim 1, wherein the E1A and E1B regions of the
25 adenovirus vector are deleted and the p53 expression region is introduced in their place.
6. The recombinant adenovirus of claim 1, which has the genome structure of Figure 1.

7. The recombinant adenovirus of claim 1, dispersed in a pharmacologically acceptable formulation.

5 8. A recombinant host cell infected with a recombinant adenovirus in accordance with claim 1.

10 9. A method of restoring wild-type p53 protein function to a cell deficient in wild-type p53 comprising, contacting the cell with an amount of the recombinant adenovirus of claim 1 effective to express wild-type p53 in the cell.

15 10. The method of claim 9, wherein the cell is a cancer cell with a mutation in a p53 gene.

20 11. The method of claim 10, wherein the cell is a human lung cancer cell.

25 12. The method of claim 10, wherein the cell is a human breast cancer cell.

13. The method of claim 9, wherein the cell is located within a mammal and the adenovirus is administered to the mammal in a pharmacologically acceptable form.

14. A method for producing recombinant adenovirus, comprising:

(a) introducing an adenovirus plasmid and an expression vector into a suitable host cell by liposome-mediated transfection; and

(b) analyzing the cultured the host cell for the presence of a cytopathic effect which is indicative of homologous recombination and virus production.

15. The method of claim 14, wherein the liposome-mediated transfection step is DOTAP-mediated transfection.

16. The method of claim 14, wherein the adenovirus plasmid is a replication-defective adenovirus plasmid and the host cell complements the defect.

17. The method of claim 16, wherein the adenovirus plasmid lacks functional E1A and E1B and the host cell is an E1-expressing cell.

18. The method of claim 17, wherein the host cell is a 293 cell.

19. The method of claim 14, wherein the host cells are cultured in MEM media.

20. The method of claim 14, further comprising obtaining DNA from the supernatant of cells exhibiting a cytopathic effect and analyzing the DNA by PCR, using expression vector-specific and adenoviral genome-specific DNA primers, to confirm the presence of the recombinant adenovirus.

5

21. The method of claim 14, wherein the expression vector comprises a p53-encoding DNA segment positioned under the control of a promoter capable of directing p53 expression in human metastatic cells.

10

ABSTRACT


Described are simplified and efficient methods for preparing recombinant adenovirus using liposome-mediated cotransfection and the direct observation of a cytopathic effect (CPE) in the transfected cells. Also disclosed are compositions and methods involving novel p53 adenovirus constructs, including methods for restoring p53 function and tumor suppression in cells and animals having abnormal p53.

10

15

20

FIGURE 1



669007-60FE460


[illegible]

Table 1

Genotype	Mean number of eggs per female	Standard deviation	Significance level
♀♂	10.8	1.2	NS
♀♀	10.6	1.1	NS
♂♂	10.9	1.3	NS
♀♂♀	10.7	1.2	NS
♀♂♂	10.8	1.1	NS
♀♀♂	10.9	1.2	NS
♂♂♀	10.7	1.1	NS
♀♀♀	10.8	1.2	NS
♂♂♂	10.9	1.3	NS
♀♂♀♂	10.7	1.2	NS
♀♂♂♀	10.8	1.1	NS
♀♀♂♂	10.9	1.2	NS
♂♂♀♀	10.7	1.1	NS
♀♀♀♀	10.8	1.2	NS
♂♂♂♂	10.9	1.3	NS







[illegible]

FIGURE 3




005004-60E4460

B

D

A

FIGURE 4



005007-60E460

FIGURE 5A




FIGURE 5B




FIGURE 6




FIGURE 7A

FIGURE 7B

FIGURE 7C




FIGURE 8




FIGURE 9A



FIGURE 9B



FIGURE 9C



FIGURE 9D



D E C L A R A T I O N

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or the below named inventors are the original, first and joint inventors (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled "Recombinant P53 Adenovirus Methods and Compositions," the Specification of which:

 is attached hereto.
 X was filed on October 29, 1993 as Application Serial No. 08/145,826.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability of the subject matter claimed in this application, as "materiality" is defined in Title 37, Code of Federal Regulations, § 1.56.

Yes/No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose all information known to me to be material to patentability of the subject matter claimed in this application, as "materiality" is defined in Title 37, Code of Federal Regulations, § 1.56, which become available between the filing date of the prior application and the national or PCT international filing date of this application:


<u>07/960,513</u>	<u>October 13, 1992</u>	<u>Pending</u>
(Application Serial No.)	(Filing Date)	(Status)
<u> </u>	<u> </u>	<u> </u>
(Application Serial No.)	(Filing Date)	(Status)

I hereby direct that all correspondence and telephone calls be addressed to Barbara S. Kitchell, Arnold, White & Durkee, P.O. Box 4433, Houston, Texas 77210 (512) 320-7200.

I hereby declare that all statements made of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

004406-004480

Inventor's Full Name: WEI-WEI ZHANG
(First) (Initial) (Last)


Inventor's Signature: 

Date: 8-30-94 Country of Citizenship: U.S. permanent residence

Residence Address : 423 Spencer's Glen
(Include number, street name, city, state, and country)
Sugar Land, TX 77479 - United States

Post Office Address:
(if different from residence address)

Inventor's Full Name: JACK A BOTH
(First) (Initial) (Last)

Inventor's Signature: 

Date: 8-30-94 Country of Citizenship: United States

Residence Address : 2324 Bolsover
(Include number, street name, city, state, and country)
Houston, TX 77004 - United States

Post Office Address:
(if different from residence address)

g:\utsc\350\pto\decl.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:	§	
Wei-Wei Zhang	§	
Jack A. Roth	§	
Serial No.: 08/145,826	§	Examiner: Unknown
Filed: October 29, 1993	§	Group Art Unit: Unknown
For: RECOMBINANT P53 ADENOVIRUS	§	Atty. Dkt: UTSC:350/KIT
METHODS AND COMPOSITIONS	§	

ELECTION UNDER 37 C.F.R. §§ 3.71 and 3.73
AND POWER OF ATTORNEY

Commissioner of Patents
and Trademarks
Washington, D.C. 20231

Sir:

The undersigned, being Assignee of record of the entire interest in the above-identified application by virtue of an assignment filed concurrently, hereby elects, under 37 C.F.R. § 3.71, to prosecute the application to the exclusion of the inventors.

The Assignee hereby revokes any previous Powers of Attorney and appoints Louis T. Pirkey, Reg. No. 22,393; Floyd R. Nation, Reg. No. 27,580; William D. Raman, Reg. No. 29,578; J. Paul Williamson, Reg. No. 29,600; Willem G. Schuurman, Reg. No. 29,998; David D. Bahler, Reg. No. 30,932; Daniel S. Hodgins, Reg. No. 31,026; David L. Parker, Reg. No. 32,165; Richard J. Groos, Reg. No. 32,231; William G. Barber, Reg. No. 33,154; Denise L. Mayfield, Reg. No. 33,732; Barbara S. Kitchell, Reg. No. 33,928; Gary J. Sertich, Reg. No. 34,430; Michael S. Metteauer, Reg. No. 34,875; Eric B. Meyertons, Reg. No. 34,876; Donald G. Jones, Reg. No. 35,560; Gloria Vaaler, Reg. No. 36,706; Richard D. Egan, Reg. No. 36,788; Amber L. Hatfield, Reg. No. 36,824; and Mark B. Wilson, Reg. No. 37,259; each a member, associate or employee of the firm of ARNOLD, WHITE & DURKEE, as attorney or agent for so long as they remain with such firm, with full power of substitution and revocation, to prosecute the application, to make alterations and amendments therein, to transact all business in the Patent and Trademark Office in connection therewith, and to receive the Letters Patent.

Pursuant to 37 C.F.R. § 3.73, the undersigned has reviewed the evidentiary documents, specifically the Assignment to Board of Regents, The University of Texas System, referenced below, and certifies that to the best of my knowledge and belief, title remains in the name of the Assignee.


Please direct all communications as follows:

Barbara S. Kitchell, Esq.
ARNOLD WHITE & DURKEE
P.O. Box 4433
Houston, Texas 77210
(512) 320-7200

ASSIGNEE:

BOARD OF REGENTS, THE
UNIVERSITY OF TEXAS SYSTEM

By:


Name: Ray Farabee
Title: Vice Chancellor
and General Counsel

Date:


January 3, 1994

ASSIGNMENT: Concurrently Filed

utsc\350\pto\power